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SUMMARY 
Exaggerated systemic inflammatory response syndrome may lead to multiple organ 
dysfunction, organ failure and eventually death. Acute pancreatitis is a mainly non-
infective cause of systemic inflammatory response syndrome while sepsis is an 
infective cause of systemic inflammatory response syndrome. These two conditions 
share indistinguishable haemodynamic features as well as a very similar profile of 
inflammatory mediators, suggesting that the devastating consequences of the two 
diseases may result from similar pathogenic mechanisms. Among the numerous 
inflammatory mediators that have been characterized in the recent years, we may have 
the opportunity to discover promising drug targets for these diseases. Chemokines, a 
large family of small chemotactic cytokines, are critical inflammatory mediators in 
the development of both acute pancreatitis and sepsis. By binding to their seven-
transmembrane-domain G protein-coupled receptors, chemokines regulate the 
activation and migration of leucocytes during acute inflammation. Previous studies by 
gene targeting or inhibitors have shown that several members of chemokines and their 
receptors are very attractive drug targets for acute pancreatitis and sepsis. However, it 
is still not known whether small molecule antagonists targeting at specific chemokine 
receptors will have protective effect against damaging systemic inflammatory 
response during acute pancreatitis and sepsis. Moreover, other new approaches to 
manipulate chemokine system are yet to be discovered. In this study, chemokine 
system in the animal models of acute pancreatitis and sepsis was manipulated by three 
different strategies: 1. blockage of specific chemokine receptor by a small molecule 
antagonist; 2. depletion of mast cell by compound 48/80 3. administration of 
exogenous soluble form of CX3C chemokine fractalkine. The impacts of each 
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strategy on the outcomes of the two diseases and the underlying mechanisms by 
which chemokines influence systemic inflammatory response have been investigated. 
 
In the first part of the study, treatment with BX471, a small molecule CCR1 
antagonist, results in significant protection against acute pancreatitis associated lung 
injury and sepsis associated lung and liver injury by attenuating neutrophil infiltration. 
In both conditions, blocking CCR1 leads to a down-regulation of P-selectin, E-
selectin and ICAM-1 in different organs, suggesting a complex interaction between 
chemokines and adhesion molecules on endothelial cells 
 
In the second part of the study, depletion of mast cells by compound 48/80 leads to 
down-regulation of various chemokines in lung in caerulein-induced acute 
pancreatitis and cecal ligation and puncture (CLP)-induced sepsis. Moreover, 
depletion of mast cells has a protective effect against acute pancreatitis-associated 
lung injury and sepsis-associated lung injury by attenuating neutrophil infiltration.  
 
In the third part of the study, administration of recombinant soluble fractalkine leads 
to an increase of neutrophil infiltration and an increase of several cytokines and 
chemokines in lung during acute pancreatitis. In contrast, treatment with soluble 
fractalkine attenuates leukocyte adhesion and infiltration in animal model of sepsis. 
Treatment with soluble fractalkine has a protective effect against sepsis-associated 
lung injury by reducing neutrophil infiltration, leukocyte adhesion and chemokine and 
cytokine production in lung.  
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These promising findings validate that manipulating chemokine system by these 
strategies may have protective effect in systemic inflammatory response in animal 
models of acute pancreatitis and sepsis. These results also show that in both acute 
inflammatory conditions, chemokines may interact with adhesion molecules, 
cytokines and control neutrophil infiltration. The therapeutic potential of small 
molecule CCR1 antagonists in acute pancreatitis and sepsis is yet to be tested in 
human clinical trials. New drug targets in the chemokine system need to be identified 
in the future. 
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LIST OF ABBREVIATIONS 
AM Alveolar macrophages 
AP Acute pancreatitis 
APC Activated protein C 




CLP Cecal ligation and puncture 
CSE Cystathionine-gamma-lyase 
ERK Extracellular signal-regulated kinases 
FAEEs Fatty acid ethanol esters  
FTK Fractalkine 
GAG Glycosaminoglycans  
GPCRs  G protein-coupled receptor 
H2S Hydrogen sulfide 
i.p. Intraperitoneal 
i.v. Intravenous 
ICAM-1 Intercellular adhesion molecule-1 
IKKs IkappaB kinase kinases 
IL Interleukin 
JNK c-Jun N-terminal kinases  
LPS Lipopolysaccharide  
MAPK Mitogen-activated protein  kinases  
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MCP-1 Monocyte chemotactic protein-1 
MIP-1a Macrophage inflammatory protein 1 alpha  
MIP-2 Macrophage-inflammatory protein-2 
MODS Multiple organ dysfunction syndrome 
MPO Myeloperoxidase  
NK1R Neurokinin 1 receptor 
PAG DL-propargylglycine 
PAMPs Pathogen associated molecular patterns 
PPT-A Pre-protachykinin-A  
PRRs Pattern recognition receptors 
RANTES Regulated on activation, normal T-cell expressed and secreted  
SIRS Systemic inflammatory response syndrome  
SP Substance P 
TAK1  Transforming growth factor-b-activated activated kinase 1 
TLR Toll-like receptors  
TNF- Tumor necrosis factor alpha 
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I. General introduction 
1.1 General overview 
Inflammation (Latin, inflammatio, to set on fire) is a complex biological response of 
the organism to harmful stimuli, such as pathogens, damaged cells, or irritants. 
Classic symptoms of inflammation were characterized by Celsus nearly 2000 years 
ago: rubor (peripheral vasodilatation with increased blood flow), calor (increased 
skin temperature due to peripheral vasodilatation), dolor (pain), and tumor (swelling 
due to increased capillary permeability). Functio laesa (loss of the functions) was 
added to the definition of inflammation by Rudolf Virchow in the 19th century (Goris, 
1996). Although the complex pathophysiology of acute inflammation is gradually 
becoming better understood, in modern hospitals acute inflammation continues to be a 
main threat to patient’s health.  
 
Local inflammation is tightly regulated by immune system and nervous system to 
combat invading pathogens or remove local injured cells. If local inflammatory 
response fails to contain the insults, systemic inflammation may occur. In general 
term, systemic inflammatory response syndrome (SIRS) is an entire normal response 
to injury or infection. However, if over-activated, it may lead to excessive leukocyte 
activation, multiple organ dysfunction syndrome (MODS), organ failure and 
eventually death. At the late irreversible stage, even the removal of initial local 
inflammatory stimulus may have no effect on the progression of organ failure and 
mortality (Latifi et al., 2002).  
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Non-infective causes of SIRS include acute pancreatitis, burns, trauma, or major 
elective surgery. On the other hand, sepsis is defined as a SIRS in which there is an 
identifiable focus of infection caused by bacterial pathogens, viruses, fungi, or 
parasites (Matsuda and Hattori, 2006). The systemic effects of acute pancreatitis and 
sepsis are very similar. In these two conditions the haemodynamic features of 
cardiovascular instability, reduced ejection fraction and decreased systemic vascular 
resistance are indistinguishable (Wilson et al., 1998). Moreover, these two conditions 
share many inflammatory mediators, such as cytokines (TNF-, IL-1, IL-6, IL-10 and 
etc), chemokines, substance P, nitric oxide, hydrogen sulfide and etc, suggesting that 
they may share some similar pathogenic mechanisms despite the different initial 
stimuli.  
 
Neutrophil infiltration and activation is a hallmark of SIRS. Neutrophils play a vital 
role in host defense by releasing proteolytic enzymes and production of reactive 
oxygen species to degrade internalized pathogens. However, excessive production of 
these lytic factors by overwhelming activated neutrophils may correlate with host 
tissue damage and organ failure during both sepsis and acute pancreatitis.  
 
In the last two decades, chemokines, a large family of chemotactic cytokines, have 
been identified and characterized. Chemokines can control leukocyte migration and 
infiltration into the tissue. Therefore, if we have the capability of controlling 
neutrophil migration and infiltration during SIRS by manipulating the chemokine 
system, we may discover new therapeutic approaches for these clinical conditions. 
The aim of the present study is to validate the hypothesis that intervening chemokine 
systems by different strategies can confer protective effect against systemic 
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inflammatory response in animal models of SIRS: acute pancreatitis and sepsis. 
Moreover, our study will also reveal some underlying mechanisms by which 
chemokines influence systemic inflammatory response during the development of 
SIRS and MODS. In the next section literature review, some background information 
about inflammation will be reviewed and then the two diseases: acute pancreatitis and 
sepsis will be discussed in greater detail. 
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1.2 Literature review 
1.2.1 Inflammation 
A lot of insults including mechanical injury, infectious pathogen, chemical injury, 
burn, radiation and tissue injury, shock, can induce acute inflammation. The early 
stage of acute inflammation consists of a complex sequence of events at tissue level: 
vessel dilation, increased vascular permeability, increased blood flow, thrombosis, 
leukocyte infiltration, release of protease, formation of oxygen free radical (Schmid-
Schonbein, 2006). The primary purpose of this stage is to eliminate antigen, pathogen, 
or damaged tissue and to clear the way for repair and rebuilding.  
 
If the local inflammation is very strong, it may lead to SIRS. Systemic leukocyte 
activation is a direct consequence of SIRS. Over-activated leukocytes spill into the 
general circulation and some are entrapped in the microcirculation of remote organs 
(such as lungs and liver) (Bhatia and Moochhala, 2004). As the condition develops, 
leukocytes migrate into the inflamed tissues through the endothelium. Great amounts 
of pro-inflammatory mediators that are produced during SIRS trigger systemic 
damage to endothelial cell. Consequently, vascular permeability is increased, edema 
occurs, and oxygen availability to the mitochondria is impaired. Therefore, the distant 
organs that are not involved in the initial local inflammation may become victims. 
Excessive SIRS may lead to MODS, organ failure and eventually death.  
 
Emerging evidence suggests that early events in acute inflammation engage an active, 
coordinated resolution program at the late stage of inflammation. New lipid mediators 
including lipoxin, resolvins, and protectins dominate this inflammation resolution 
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stage. Lipoxin, for example, can reduce new neutrophil infiltration, reduce vascular 
permeability, promote monocyte infiltration and induce macrophage phagocytosis 
(Serhan and Savill, 2005). Phagocytosis of apoptotic neutrophils by macrophages 
leads to both neutrophil clearance and release of anti-inflammatory cytokines such as 
TGF- and IL-10. At the end of this resolution stage, inflamed tissue may restore its 
physiological function. If the pathogens or noxious insults persist, the inflammatory 
cascade may progress into a chronic inflammation.  
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1.2.2 Acute pancreatitis 
Acute pancreatitis (AP) is defined as an acute inflammatory process of the pancreas 
that frequently involved peripancreatic tissues and at times remote organ systems. It is 
one of the most frequent causes of acute inflammatory states in the abdomen. About 
40 cases of AP per 100,000 adults are reported every year (Granger and Remick, 
2005). Nearly 80% of the patients have a self-limiting course and recover in a few 
days. The other 20 % may require intensive care treatment for hemorrhagic and 
necrotic lesions of the pancreas with a mortality rate of 40%. There are two situations 
among mortal cases in acute pancreatitis. Patients who die from acute pancreatitis 
within the first week, suffer a severe initial attack and develop exaggerated SIRS with 
the development of MODS (Gomez-Cambronero et al., 2002). Patients with a severe 
attack who even though survive the initial overactive SIRS insult, often die later 
following a relatively minor second event that would not normally be life-threatening, 
such as a line or chest infection. However, recovery is possible if no further insult 
occurs. At present, there is no treatment against severe acute pancreatitis, other than 
supportive critical care (Gomez-Cambronero et al., 2002).  
 
1.2.2.1 Causes of acute pancreatitis 
It is known that alcohol abuse and gallstone disease account for 70-80% of the cases 
of acute pancreatitis. However, the exact triggering mechanisms for acute pancreatitis 
are presently not established. Alcohol abuse in humans is a risk factor for pancreatic 
necrosis during acute pancreatitis. However, only a minority of population who abuse 
alcohol develop pancreatitis and alcohol feeding alone usually fails to induce 
pancreatitis in animals, indicating that that alcohol abuse may sensitize individuals to 
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pancreatitis. It has been shown that ethanol sensitizes NF-κB activation in pancreatic 
acinar cells through its effects on protein kinase C (Gukovskaya et al., 2004; Satoh et 
al., 2006). Ethanol feeding also induces a decrease in caspase expression and an 
increase in cathepsin B expression, indicating that ethanol abuse may prevent 
apoptosis of pancreatic cells and activate trypsinogen with stresses that cause 
pancreatitis (Wang et al., 2006). Moreover, in the pancreas non-oxidative metabolism 
of ethanol  leads to fatty acid ethanol esters (FAEEs) synthesis (Pandol et al., 2007). 
Recent study shows that FAEEs cause a sustained increase of cytosolic calcium 
concentration in pancreatic acinar cells that leads to mitochondrial injury and 
impaired ATP production (Criddle et al., 2006). 
 
Gallstone pancreatitis is caused when a migrating gallstone obstructs the ampulla of 
vater. The obstructing stone forms a common channel and increased pressure between 
the common bile duct and pancreatic duct, which results in the reflux of biliary 
contents into the pancreas. Multiple studies in animals have shown that transporter-
mediated bile acid uptake causes calcium-dependent cell death of pancreatic acinar 
cells and activation of NF-κB (Kim et al., 2002; Vaquero et al., 2001). However, roles 
for bile acids in human pancreatitis have not been demonstrated yet. 
 
1.2.2.2 Pathophysiology of acute pancreatitis 
1.2.2.2.1 First phase: the initial stage of pancreatic acinar 
cell damage 
Under normal conditions, the digestive enzymes are synthesized and secreted by the 
acinar cells as inactive proenzymes called zymogens. Zymogens are activated in the 
duodenum where enterokinase activates trypsinogen. Subsequently, trypsin induces 
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the activation of itself as well as other digestive enzymes including 
chymotrypsiongen, procarboxypeptidase and proelastase. In contrast, at the early 
stage of acute pancreatitis, those zymogens become prematurely activated within 
pancreatic acinar cells. The mechanisms responsible for intra-acinar activation of 
digestive enzyme zymogens have not been fully understood. However, according to 
one widely recognized theory (the "co-localization hypothesis"), pancreatic zymogens 
are colocalized with lysosomal enzymes and thus activated by lysosomal enzymes 
such as cathepsin B. The colocalization of lysosomes with zymogen granules has been 
demonstrated by immunolocalization studies (Watanabe et al., 1984). It has also been 
shown that Cathepsin B inhibitors and gene deficiency can prevent in vitro caerulein-
induced trypsinogen activation and attenuate in vivo severity of acute pancreatitis 
(Halangk et al., 2000; Saluja et al., 1997; Van Acker et al., 2002).  
 
It appears that not only enzymogen activation but also enzymogen retention inside the 
acinar cells may be required for the pathogenesis of acute pancreatitis. Caerulein, an 
analogue of CCK, has biphasic dose response curve for pancreatic secretion. Only the 
supermaximal dose of caerulein that inhibits pancreatic secretion can induce acute 
pancreatitis, while other doses that stimulate pancreatic secretion fail to induce acute 
pancreatitis (Saluja et al., 1989). In contrast, CCK-JMV-180 (another analogue of 
CCK) and bombesin have a monophasic dose response curve for amylase secretion, 
indicating that they have no inhibitory effect on the rate of secretion. (Powers et al., 
1993; Saluja et al., 1989). Experiments confirm that in contrast to caerulein, 
supermaximal dose of these two compounds fail to induce acute pancreatitis (Powers 
et al., 1993; Saluja et al., 1989). 
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Calcium appears to be involved in zymogen activation as well. Pathological intra-
acinar zymogen activation is associated with an aberrant rise in acinar cell 
intracellular calcium concentration (Ward et al., 1996). When this Cai2+ rise is 
prevented, CCK-induced trypsinogen activation is also blocked (Raraty et al., 2000). 
However, whether calcium by itself is sufficient to induce zymogen activation and 
acute pancreatitis is still controversial. 
 
1.2.2.2.2 Second phase: local inflammation 
The local pancreatic inflammation is characterized by the activation of transcription 
factor NF-kappa B and production of a variety of inflammatory mediators in the 
pancreas. The pro-inflammatory cytokines including Tumor necrosis factor- (TNF-
), Interleukin (IL)-1, IL-6, anti-inflammatory mediators including IL-10, IL-1 
receptor antagonist, chemokines including IL-8 and MCP-1, and adhesion molecules 
including selectins and ICAM-1 are all involved in this response. Production of some 
cytokines and chemokine results in the infiltration of inflammatory cells such as 
neutrophils and macrophages. The infiltration and activation of neutrophils leads to a 
further elevation of the inflammatory mediators and pancreatic acinar cell injury. The 
severity of the disease seems to be determined by the events occurring at this phage. 
 
1.2.2.2.3 Third phase: systemic inflammation 
Most patients who suffer from the pancreatic injury and local inflammation recover 
with pancreatitis resolved. However, in some patients the disease develops to SIRS. 
These patients are at high risk of remote organ failure. Pancreatitis-associated lung 
injury, manifesting as adult respiratory distress syndrome (ARDS), is the most 
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frequent sign of MODS. ARDS is characterized by increased permeability of the 
alveolar–capillary barrier, resulting in influx of protein rich edema fluid and 
consequently impairment in arterial oxygenation (Reutershan and Ley, 2004). 
Infiltration and activation of neutrophils appear to play an important role in the 
development of ARDS, because the depletion of neutrophils attenuates lung injury in 
several animal models (Abraham et al., 2000; Bhatia et al., 1998).  
 
1.2.2.2.4 Inflammatory mediators in AP 
Inflammatory mediators appear to play a critical role in the second and third phase of 
pathogenesis of acute pancreatitis. Many mediators are first produced in pancreas and 
increase the local pancreatic injury, and then spread into the general circulation and 
distant organs, contributing to the progression from local inflammation to severe 
systemic disease.  
 
TNF- and IL-1 are mainly derived from activated macrophages and act via cell 
membrane bound receptors. Intrapancreatic and serum TNF- is detectable 1hour 
after the induction of acute pancreatitis and increase over 6 hours (Norman et al., 
1995). Clinical pancreatitis is associated with high circulating levels of IL-1, with 
serum concentrations correlating with morbidity and mortality rates (McKay et al., 
1994). In a bile-infusion model of pancreatitis in the rat, researchers have shown that 
blockage of TNF- by anti-TNF alpha polyclonal antibody ameliorates disease 
severity and increases survival rate (Hughes et al., 1996). It has also been shown that 
posttranscriptional blockade of TNF- production results in dramatic reductions in 
tissue damage and pancreatitis severity in two different models of acute pancreatitis 
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(Denham et al., 1997) Similarly, blockade of IL-1 receptor decreased severity of 
pancreatitis (Norman et al., 1995) . Although promising results have been observed in 
animal models, transition to clinical practice seems challenging (Malleo et al., 2007).  
 
Substance P is an 11 amino acid neuropeptide (RPKPQQFFGLM-NH2) that is 
released from nerve endings in many tissues. It is derived from the product of pre-
protachykinin-A (PPT-A) gene and expressed almost exclusively in the central and 
peripheral nervous systems (Carter and Krause, 1990). Substance P binds 
preferentially to neurokinin1 receptors (NK1R) on effector cells and works as a 
mediator of pain as well as inflammation. Pancreatic acinar cells are known to express 
NK1R and substance P has been detected within the pancreas (Osman et al., 1998; 
Patto et al., 1992; Sjodin and Gylfe, 1992). It has been shown that  in NK1R knockout 
mice  the severity of pancreatitis and associated lung injury is attenuated (Bhatia et 
al., 1998). Furthermore, PPT-A gene knockout and treatment with NK1R antagonist 
also show a protective effect against acute pancreatitis and associated lung injury 
(Bhatia et al., 2003; Lau et al., 2005). These observations indicate that substance P, 
acting through NK1R, plays an important proinflammatory role in regulating the 
severity of AP and associated lung injury. Substance P acts on endothelial cells, 
leading to vasodilation and edema formation (Liddle and Nathan, 2004). Moreover, 
recent studies have revealed that substance P may induce chemokine synthesis during 
acute pancreatitis (Bhatia et al., 2005; Sun and Bhatia, 2007). 
 
Hydrogen sulphide (H2S) has been well known for several decades as a toxic gas with 
the smell of rotten eggs. Recent studies begin to reveal that H2S act as a important 
biological mediator (Bhatia et al., 2005; Feterowski et al., 2004; Lowicka and 
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Beltowski, 2007; Wang, 2002). H2S is degraded rapidly in the body, either chemically 
(by the putative H2S metabolizing enzymes thiol S-methyltransferase and rhodanese), 
or by sequestration with macromolecules (Damas et al., 2005). Two key enzymes 
cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS) utilize L-
cysteine as substrate to form H2S. The expression of CSE is identified in the pancreas 
and treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly 
reduced the severity of caerulein-induced pancreatitis and associated lung injury 
(Bhatia et al., 2005). One recent study of our group has shown that in pancreatic 
acinar cells H2S may exert its pro-inflammatory effect through substance P and NK-
1R mediated pathway (Tamizhselvi et al., 2007). 
 
1.2.2.3 Caerulein-induced acute pancreatitis 
Investigators have developed numerous experimental animal models of AP. 
Generally, the models can be differentiated according to (a) induction technique in 
invasive and noninvasive models, (b) cause (biliary, obstructive, alcoholic, toxic, etc), 
or (c) degree of severity (mild/edematous vs. severe/necrotizing) (Foitzik et al., 
2000). Among them, caerulein-induced mouse acute pancreatitis model was chosen 
for this study. Compared to those invasive pancreatitis models characterized with 
extensive and uncontrolled pancreatic destruction, this model is relative noninvasive, 
nonlethal, easy to use, inexpensive, and highly reproducible. This widely used model 
of caerulein-induced pancreatitis provides an experimental system for accurately 
examining the onset and development of experimental pancreatitis.  
 
Cholecystokinin (CCK) is a peptide hormone of the gastrointestinal system 
responsible for stimulating the digestion of fat and protein. Released from the 
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duodenum, the hormone acts on the pancreas to stimulate the secretion of a juice rich 
in digestive enzymes, including trypsinogen, chymotrypsinogen, amylase, lipase, and 
maltase. CCK stimulates protein secretion in a dose dependent manner. Doses of CCK 
that provide continued maximal stimulation of enzyme secretion are associated with 
increased rates of protein synthesis. However, if the maximal stimulation persists for a 
period of time, the increase of protein synthesis will be outpaced by the rate of protein 
secretion and results in reduction of enzyme stores of the exocrine pancreas (Scheele 
and Palade, 1975). Distinctly, supermaximal stimulation, namely, increasing the dose 
of CCK by an order of magnitude over the levels that produce maximal secretion, 
generates a paradoxical pancreatic response, which includes diminished secretion, 
accumulation of secretory proteins within the pancreas, and pancreatic injury (Lampel 
and Kern, 1977).  
 
Caerulein is an amphibian peptide that has the same biologic activity as CCK. 
Supermaximal doses (50 μg/ kg) of caerulein have been found to induce severe acute 
pancreatitis in mice and results in pancreatic damage characterized by edema, 
increased serum levels of pancreatic enzymes, inflammation and necrosis. The most 
often used approach to build up this model is to give mice (Swiss mice, male or 
female, 4 to 5 weeks old) hourly intraperitoneal injections of saline containing a 
supermaximally stimulating concentration of caerulein (50 μg/ kg) for 10 or 12 hours 
(Bhatia et al., 2000; Bhatia et al., 1998).  
 
1.2.2.3.1 Amylase 
In human pancreatitis, one of its hallmarks is an increase in the level of pancreatic 
enzymes within the serum. In mouse caerulein-induced pancreatitis, serum levels of 
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amylase increased rapidly in time-dependent manner. Although the mechanism 
responsible for this phenomenon is still unknown, it is possible that enzymes may 
gain entry into the interstitial and intravascular space following pathological 
exocytotic release at the basolateral membrane of the acinar cell. Alternatively, 
changes in junctional permeability may allow enzymes to pass from the pancreatic 
duct into interstitium.  
 
1.2.2.3.2 Pancreatic edema 
The formation of pancreatic edema during caerulein hyperstimulation is probably due 
to a distinct mechanism, since some time it is observed to be unparallel to other 
parameters of pancreatitis. It is probably due to the combination of the following 
factors: 1) increased vascular permeability, 2) increased hydrostatic pressure from 
small vessel constriction or obstruction, and 3) increased tissue oncotic pressure.  
 
1.2.2.3.3 Pancreatic acinar cells injury/necrosis 
Repeated hourly injections of high doses of caerulein are associated with diminished 
pancreatic secretion and a highly reproducible time-dependent pancreatic injury 
including acinar cell vacuolization and necrosis. Within 10hr of caerulein-induced 
pancreatitis acinar cells exhibit cell injury evidenced by  (i) the presence of acinar-cell 
ghosts; or (ii) vacuolization and swelling of acinar cells and the destruction of the 
histoarchitecture of whole or parts of the acini examined by light microscopy (Bhatia 
et al., 2000; Bhatia et al., 2003; Bhatia et al., 2005; Bhatia et al., 1998). Besides cell 
swelling, the electron microscopy changes of pancreatic acinar cell injury include 
(i)dilatation of the endoplasmic reticulum, (ii)condensation of nuclear chromatin, 
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(iii)loss in the definition of the plasmalemmal membrane, (iv)formation of large 
cytoplasmic vacuoles near the Golgi complex, and (v)disruption of apical domain of 
the cell which may be shed into the acinar lumen (Gorelick et al., 1993). All these 
cellular change are associated with an inflammatory reaction.  
 
1.2.2.3.4 Lung injury 
Caerulein induced pancreatic hyper-stimulation is associated with the development of 
an acute lung injury which is characterized by neutrophil infiltration from the 
pulmonary microvasculature, increased vascular permeability as well as interstitial 
edema which are very similar to the features of ARDS (Zhao et al., 2002). In rat lungs 
that are isolated immediately after the caerulein infusion, pressor responses to 
angiotensin II and acute hypoxia is decreased (Feddersen et al., 1991). In caerulein-
induced acute pancreatitis in mice, lung injury is not evident until 6 hours after the 
first dose of caerulein. The changes in pulmonary vascular reactivity are reversible 2 
to 3 days after induction of acute pancreatitis (Feddersen et al., 1991). In conclusion, 
caerulein-induced acute pancreatitis mouse model offer us an opportunity to study a 





Sepsis represents SIRS that is induced by an infection. Severe sepsis occurs when 
sepsis leads to dysfunction of at least one organ or organ system. An epidemiological 
study shows that in the United States more than 500,000 patients develop sepsis per 
year and the incidence was estimated to increase by 1.5% per year (Angus et al., 
2001). It has been estimated that the annual costs for treatment of sepsis are $16.7 
billion in USA alone. The mortality rate ranges between 30% and 47% (Riedemann et 
al., 2003). The commonest sites of infection are the lungs, abdominal cavity, the 
urinary tract and primary infections of the blood stream (Cohen, 2002).  
 
1.2.3.1 Pathophysiology of sepsis 
1.2.3.1.1 Recognition of pathogens 
Various invading pathogens including Gram-negative bacteria, Gram-positive bacteria 
as well as fungus, may be the initial cause of sepsis. Innate immune system employs 
pattern recognition receptors (PRRs) to recognize highly conserved components on 
these pathogens: pathogen associated molecular patterns (PAMPs). Toll-like receptors 
(TLRs) are the most thoroughly studied PRRs. TLRs have 10 members and all of 
them are expressed in human neutrophils except TLR3 at least at mRNA levels 
(Hayashi et al., 2003). TLR4 acts as the main lipopolysaccharide (LPS) receptor, 
while TLR2 acts as the main receptor for Gram-positive cell-wall components, 
including peptidoglycan and lipoteichoic acid, as well as mycobacterial cell-wall 
components such as lipoarabinomannan and mycolylarabinogalactan, and yeast cell-
wall zymosan (Underhill et al., 1999).  
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After TLRs are activated by their ligands, MyD88 is associated with TLR complex as 
the adaptor molecule, which lead to the formation of the complex of interleukin-1 
receptor associated kinase 4 (IRAK4)/IRAK-1/Tumor necrosis factor-associated 
factor 6 (TRAF6) (Ye et al., 2002). This complex interacts with another complex that 
is comprised of transforming growth factor-beta-activated kinase 1 (TAK1), TAK1-
binding protein 1 (TAB1), and TAB2 (Shibuya et al., 1996; Takaesu et al., 2000). 
TAK1 is subsequently activated in the cytoplasm, leading to the activation of IkappaB 
kinase kinases (IKKs) (Shibuya et al., 1996). IKK activation leads to phosphorylation 
and degradation of IkappaB, translocation of NF-κB into the nucleus, and up-
regulation of the expression of inflammatory cytokines and chemokines. Through this 
pathway, TLRs activate neutrophils, macrophages, endothelial cells and epithelia to 
produce inflammatory mediators including cytokines and chemokines. TLRs 
activation can induce the expression adhesion molecules on the endothelial cells 
either directly or indirectly through pro-inflammatory cytokines TNF- and IL-1 
(Parker et al., 2005). These consequences promote neutrophil migration to the site of 
inflammation during sepsis.  
 
1.2.3.1.2 Pro-inflammatory cytokines 
Pro-inflammatory cytokines including TNF- and IL-1 are produced within the first 
30-90 min after LPS administration and lead to further activation of inflammatory 
cascades including cytokines, lipid mediators, reactive oxygen species and adhesion 
molecules (Cohen, 2002). The impact of these pro-inflammatory cytokines in sepsis 
seems significant because high levels of TNF-, IL-6 and IL-1 in septic patients are 
correlated with higher risk for death (Waage et al., 1989; Waage et al., 1987) and 
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injection of TNF- into experimental animal results in a sepsis-like response (Remick 
et al., 1987). However, a series of clinical trials by blocking TNF or IL-1 fail to show 
a dramatic improvement in survival (Remick, 2003).  
 
1.2.3.1.3 Substance P  
High substance P levels have been identified as late predictive indicators of lethal 
outcome in patients with postoperative sepsis (Beer et al., 2002). Our group has 
shown that deletion of the PPT-A gene (encoding substance P and neurokinin A) 
attenuates inflammatory cells infiltration and protects against tissue damage in mouse 
model of sepsis (Puneet et al., 2006). Treatment with NK1R (substance P receptor) 
antagonist also have a beneficial effect on lung inflammation by reducing leukocyte 
infiltration in the same mouse model of sepsis (Bhatia and Hegde, 2007). 
 
1.2.3.1.4 Hydrogen sulfide 
Endogenous vascular H2S increases in rats models of septic shock and endotoxic 
shock (Hui et al., 2003).  In LPS-induced endotoxic shock model, H2S exhibits pro-
inflammatory activity and administration of PAG, an inhibitor of the H2S-
synthesizing enzyme, attenuates tissue injury (Collin et al., 2005; Li et al., 2005). 
Similarly, in CLP-induced sepsis model, the effect of inhibition of H2S formation and 
administration of NaHS, a H2S donor, suggests that H2S plays a pro-inflammatory 
role in regulating the severity of sepsis and associated organ injury (Zhang et al., 
2006). Further study shows that H2S up-regulates the production of pro-inflammatory 
cytokines and chemokines and exacerbates the systemic inflammation in sepsis 
through a mechanism involving NF-κB activation (Zhang et al., 2007). H2S also acts 
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as a regulator of adhesion molecules and chemokine receptor CXCR2 during sepsis 
(Zhang et al., 2007). Interestingly, in sepsis, H2S may up-regulate the production of 
SP as well, which activate NK-R1 and lead to acute lung injury (Zhang et al., 2007). 
 
1.2.3.1.5 The coagulation cascade 
The normal homeostatic balance is impaired during sepsis. Pro-coagulant mechanism 
is activated: expression of tissue factor on mononuclear cells and endothelial cells is 
enhanced where it activates a series of proteolytic cascades that lead to the production 
of thrombin from prothrombin, which in turn generates fibrin from fibrinogen. On the 
other hand, anti-coagulant mechanism is impaired: levels of the plasminogen-activator 
inhibitor-1 are increased during sepsis, which leads to reduced generation of plasmin 
from plasminogen, which in turn reduces the fibrin breakdown (Cohen, 2002). The 
net result is enhanced formation of fibrin clots in the microvasculature, leading to 
impaired tissue perfusion and organ failure. 
 
Activated protein C (APC) is converted from protein C when thrombin complexes 
with throbomudulin. APC with its cofactor protein S acts as proteolytic inhibitor of 
the clotting factors Va and VIIa. Moreover, APC increases the fibrinolytic response 
by inhibiting the activity of plasminogen-activator inhibitor-1 (Healy, 2002). APC 
also have anti-inflammatory effects by reducing TNF-, IL-1 and IL-6 production 
from monocytes and reducing adhesive interactions between neutrophils and 
endothelial cells (Healy, 2002). Levels of APC are dramatically down-regulated in 
sepsis which is correlated with poor outcome. These studies have finally lead to the 
development of a recombinant human form of endogenous APC (drotrecogin alfa) 
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that was approved by the Food and Drug Administration of USA for severe sepsis in 
adults who have a high risk of death.  
  
1.2.3.1.6 Apoptosis and immune suppression 
Initially, sepsis may be characterized by the storm of inflammatory mediators; 
however, if sepsis persists, an anti-inflammatory immunosuppressive state will appear 
leading to a hypo-reactive host defense system and immunoparalysis. Apoptosis of 
several types of cells may attribute to immune suppression. Mediators including 
steroids, TNF-, nitric oxide, C5a, Fas ligand appear to contribute to apoptosis 
(Wesche-Soldato et al., 2005). It has been shown that septic patients have significant 
apoptosis of lymphocytes (Hotchkiss et al., 2001). The number of B cells, CD4 T 
cells and follicular dendritic cells is markedly decreased in patients who died of 
sepsis, as compared to patients with trauma (Hotchkiss et al., 2003). On the other 
hand, apoptosis also contribute to the mucosal epithelial cell loss and dysfunction 
during experimental sepsis (Coopersmith et al., 2002). It has also been reported that 
vascular endothelial cells go through apoptosis after CLP operation (Zhou et al., 
2004). Therefore, in sepsis apoptosis directly leads to loss of functional immune and 
non-immune cells. Moreover, clearance of apoptotic cells may induce phagocytes 
including macrophages and dendritic cells, and CD4 T cells to release anti-
inflammatory cytokines that contribute to immune suppression.   
 
As inhibiting Fas-FasL signaling (e.g., Fas fusion protein (Chung et al., 2003), or Fas 
siRNA administration (Wesche-Soldato et al., 2005)), caspase inhibition (caspase 
gene deficiency and inhibitor (Hotchkiss et al., 2000) ), and the overexpression of 
downstream anti-apoptotic molecules (e.g., Bcl-2 (Hotchkiss et al., 1999), Akt 
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(Bommhardt et al., 2004)) increase survival rate of septic mice, it not only 
demonstrates the pathological significance of this process but points to novel targets 
for the treatment of sepsis 
 
1.2.3.2 Animal models of sepsis 
Based on the initial agent, sepsis models can be divided into three categories: 
exogenous administration of a toxin (such as LPS, endotoxins or zymosan); 
exogenous administration of a viable pathogen (such as bacteria); or alteration of the 
animal’s endogenous protective barrier (inducing colonic permeability, allowing 
bacterial translocation). All these models have contributed significantly to our 
understanding of host defense mechanism against infection. However, many 
therapeutic agents that were effective in animal models fail to show a similar 
protective effect in human clinical trials in the past 40 years. A crucial problem in 
most of the clinical trials investigating anti-inflammatory agents in sepsis appears to 
be the non-homogeneity of the patient population enrolled, which partially stems from 
an inability to more effectively classify the immune status of patients (Riedemann et 
al., 2003). Two drawbacks common to all sepsis models with respect to clinical 
relevance are the timing of disease development and lack of supportive therapeutic 
interventions (Buras et al., 2005). The onset and progression of sepsis to multi-organ 
failure occurs in hours to days in most animal models, whereas in human patients this 
progression occurs over days to weeks. Furthermore, human patients are promptly 
treated with various standard therapies such as source control (identification of 
infection with physical removal by invasive procedures), oxygen therapy, intubation 
and mechanical ventilation; fluid, antibiotic and vasopressor therapy; and nutritional 
support. Most of these supportive interventions are not available in animal models. 
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Host-barrier disruption models of sepsis involve the breaching of the normal 
protective barriers that shield normally sterile compartments from pathogens. The 
CLP model belongs to this category and is considered the gold standard for sepsis 
research (Parker and Watkins, 2001). The CLP model mimics the human diseases of 
ruptured appendicitis or perforated diverticulitis. The technique involves midline 
laparotomy, exteriorization of the cecum, ligation of the cecum distal to the ileocaecal 
valve and puncture of the ligated cecum. This procedure generates bowel perforations 
with leakage of fecal contents into the peritoneum, which establishes an infection with 
mixed bacterial flora and provides an inflammatory source of necrotic tissue. The 
CLP technique has achieved its popularity because of its ease, general reproducibility 
and similarity to human disease progression. Most notably, the CLP model recreates 
the haemodynamic and metabolic phases of human sepsis (Wichterman et al., 1980). 
Moreover, apoptosis of selected cell types and host immune responses seem to mimic 
the course of human disease, adding further clinical validity to this model (Ayala and 
Chaudry, 1996; Hotchkiss and Karl, 2003). One comparison study has shown that 
LPS causes a rapid induction of cytokines and chemokines followed by an early 
decline in mice, while CLP induces a slower sustained increase of cytokines and 




1.2.4.1 Chemokine classification 
Since interleukin-8 was identified as a leukocyte chemotactic factor two decades ago 
(Yoshimura et al., 1987), more than 40 chemokines have been identified in human 
with 70 percent homology in amino acid sequences (Luster, 1998). Majority of human 
chemokines are small proteins with molecular weight between 8kd to 12kd. They can 
be divided into four families according to the relative position of their cysteine 
residues. In the CXC chemokines, the first two cysteines are separated by an amino 
acid residue. In contrast, in the CC chemokines, the first two cysteines are adjacent to 
each other. Most human CXC chemokine genes are clustered at 4q13 while most 
human CC chemokine genes are clustered at 17q11.2-12 (Rollins, 1997). The third 
family is the CX3C family, in which the first two cysteine residues are separated by 
three amino acids. Fractalkine belongs to this family. Fractalkine carries a chemokine 
domain on top of an extended mucin-like stalk. This molecule can exist in two forms 
in vivo: either membrane-anchored or as a shed 95kd glycoprotein. The soluble 
fractalkine has potent chemotactic activity for T cells and monocytes, and the cell-
surface-bound protein, promotes strong adhesion of those leukocytes (Bazan et al., 
1997). The fourth family of chemokine, C family having only one cysteine residue 
near its N-terminus, has a member: lymphotactin. So far, most human chemokines 
have corresponding mouse counterparts. A systematic nomenclature of chemokines 









Name Human ligand Mouse ligand Chemokine receptor 
CXC chemokine-receptor family   
CXCL1 GRO/MGSA- GRO/MIP-2/KC CXCR2,CXCR1 
CXCL2 GRO/MGSA- GRO/MIP-2/KC CXCR2 
CXCL3 GRO/MGSA- GRO/MIP-2/KC CXCR2 
CXCL4 PF4 PF4 Unknown 
CXCL5 ENA-78 GCP-2/LIX CXCR2 
CXCL6 GCP-2 GCP-2/LIX CXCR1, CXCR2 
CXCL7 NAP-2 Unknown CXCR2 
CXCL8 IL-8 Unknown CXCR1, CXCR2 
CXCL9 Mig Mig CXCR3 
CXCL10 IP-10 IP-10/CRG-2 CXCR3 
CXCL11 I-TAC I-TAC CXCR3 
CXCL12 SDF-1 / SDF-1/PBSF CXCR4 
CXCL13 BCA-1 BLC CXCR5 
CXCL14 BRAK/bolekine BRAK Unknown 
(CXCL15) Unknown Lungkine/WECHE Unknown 
CXCL16   CXCR6 
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XCL2 SCM-1 Unknown XCR1 
CX3C chemokine-receptor family   
CX3CL1 Fractalkine Neurotactin/ABCD-3 CX3CR1 
CC chemokine-receptor family   
CCL1 I-309 TCA-3/P500 CCR8 
CCL2 MCP-1/MCAF/TDCF JE CCR2 
CCL3 MIP-1/LD78 MIP-1 CCR1, CCR5 
CCL3L1 LD78 Unknown CCR1, CCR5 
CCL4 MIP-1 MIP-1 CCR5 
CCL5 RANTES RANTES CCR1, 3, 5 
(CCL6) Unknown C10/MRP-1 Unknown 
CCL7 MCP-3 MARC CCR1,2,3 
CCL8 MCP-2 MCP-2 CCR3, 5 
(CCL9/10) Unknown MRP-2/CCF18/MIP-1 CCR1 
CCL11 Eotaxin Eotaxin CCR3 
(CCL12) Unknown MCP-5 CCR2 
CCL13 MCP-4 Unknown CCR2, CCR3 
CCL14 HCC-1 Unknown CCR1, CCR5 
CCL15 HCC-2/Lkn-1/MIP-1 Unknown CCR1, CCR3 
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CCL16 HCC-4/LEC/LCC-1 Unknown CCR1, CCR2 




CCL19 MIP-3/ELC/exodus-3 MIP-3/ELC/exodus-3 CCR7 
CCL20 MIP-3/LARC/exodus-1 MIP-3/LARC/exodus-1 CCR6 
CCL21 6Ckine/SLC/exodus-2 6Ckine/SLC/ 
exodus-2/TCA-4 
CCR7 
CCL22 MDC/STCP-1 ABCD-1 CCR4 
CCL23 MPIF-1/CK8/CK8-1 Unknown CCR1 
CCL24 Eotaxin-2/MPIF-2 MPIF-2 CCR3 
CCL25 TECK TECK CCR9 
CCL26 Eotaxin-3 Unknown CCR3 
CCL27 CTACK/ILC ALP/CTACK/ILC/ESkine CCR10 
CCL28 MEC  CCR3/CCR10 
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CXC chemokines can be subdivided into two subfamilies depending on the presence 
or absence of the ELR (glutamine-leucine-arginine) motif near the N-terminal. The 
ELR+ chemokines are believed to be classic neutrophil chemoattractants; while ELR- 
chemokines are believed to mainly act on lymphocytes. The massive infiltration of 
neutrophil during inflammation is often associated with the increased levels of ELR+ 
chemokines. Early clinical study has already shown high levels of IL-8 in the blood 
and alveolar spaces of patients with pneumonia and adult respiratory distress 
syndrome (Chollet-Martin et al., 1993). Other ELR+ chemokines include GRO-, 
GRO-, GRO-, ENA-78, GCP2 and Platelet basic protein.  
 
CC chemokines have been believed to be primarily monocyte chemoattractants. In CC 
chemokines, MCP1-4 are closely related monocyte chemoattractant proteins. They are 
encoded on chromosome 17 and share similar function in vitro as monocyte 
chemoattractants. Among them, MCP-1 is the most potent one (Rollins, 1997). 
Moreover, because its corresponding receptor CCR2 on neutrophils can be up-
regulated in animal model of sepsis, MCP-1 may be able to induce neutrophil 
migration in vivo (Speyer et al., 2004). 
 
CC chemokines macrophage inflammatory protein-1 and macrophage inflammatory 
protein-1 are also involved in acute inflammation. In the mouse, MIP-1α is a potent 
mediator for neutrophils recruitment and activation. In human, CCR1 is present and 
up-regulated in isolated human neutrophils after treatment with interferon-γ or 
granulocyte macrophage colony-stimulating factor and that subdermal injection of 
MIP-1 leads to neutrophil as well as monocyte influx in human volunteers 
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suggesting that these CC chemokines may also be involved in neutrophil trafficking in 
human (Bonecchi et al., 1999; Cheng et al., 2001; Lee et al., 2000).  
 
1.2.4.2 Chemokine receptors  
The biological effect of all the chemokines are mediated by a family of seven-
transmembrane-domain G protein-coupled receptors (GPCRs). Most chemokines are 
positive charged. The electrostatic interaction between the negative charged 
extracelluar loops of the chemokine receptor and the positive charged surface of the 
chemokine leads to the initial docking. After that, the ligands are steered towards the 
receptor and the receptors are activated by the amino terminus of the ligand and other 
residues close by in space. The stabilized active formation of receptor triggers the 
downstream signaling pathways (Schwarz and Wells, 2002).  
 
Nearly 20 different types of chemokine receptors have been described so far. Most of 
them are clustered on chromosome 2 and 3 (Zlotnik and Yoshie, 2000). Obviously, 
many chemokine ligands can bind to more than one receptor with high affinity, while 
many chemokine receptors have more than one ligand. Chemokine receptors are 
expressed on different types of leukocytes. Some chemokine receptors are expressed 
only on certain cells (for example, CXCR1 on neutrophils), while others are more 
widely expressed (for example, CCR2 on monocytes, T cells, NK cells, dendritic 
cells, and basophils). Besides leukocytes, some chemokine receptors are found to be 
expressed on endothelial cells, epithelial cells, neurons but their exact biological 
function is still under investigation. Moreover, the expression of many chemokine 
receptors can be regulated during acute inflammatory response. Although the complex 
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chemokine system seems redundant, some chemokines play an essential role during 
inflammatory diseases that cannot be replaced by other chemokines (Carter, 2002). 
 
1.2.4.3 Signal transduction 
The binding of chemokines to their corresponding receptors can activate a very 
complex signaling cascade that leads to leukocyte migration and activation. Some 
studies suggest that chemokine receptors may be uniformly distributed on the whole 
cellular membrane instead of accumulating on the leading edge of migrating cells 
(Xiao et al., 1997). Chemokine receptors are coupled to Gi because chemotaxis is 
entirely inhibited after the treatment with pertussis toxin. The release of  subunits 
are required for the chemokine-induced chemotaxis (Thelen, 2001). Further studies 
reveal an asymmetric distribution of intracellular signal transduction proteins during 
chemotaxis. Leukocytes adopt a polarized morphology and develop a wide pseudopod 
at the leading edge which can detect chemokine gradient and a uropod at the trailing 
end (Stossel, 1994). In an experiment using GFP-tagged  subunit, it is shown hat  
subunits are asymmetrically distributed with a higher concentration at uropod (Jin et 
al., 2000). The  subunits activate the phosphoinositide-3 kinases and lead to the 
production of PIP3 (Rot and von Andrian, 2004). Then PIP3 translocates to the 
pseudopod where it act as a docking site for protein kinase B that can activate actin 
polymerization (Servant et al., 2000). Interestingly, PKB are also involved in signal 
pathways that promote cell survival (Chan et al., 1999). Moreover, at the pseudopod 
PIP3 also activate Rac which lead to stimulate actin-related protein (Arp) 2/3. This 
pathway finally leads to focal actin polymerization that is essential for the 
development and extension of pseudopod (Rot and von Andrian, 2004). In contrast, at 
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the uropod, Gi12/13 activates Rho which induces focal activation of myosin II and 
contraction of actin-myosin complexes (Worthylake et al., 2001). 
 
Other downstream signal pathways can also be activated after the activation of 
chemokine receptors. For example,  subunits can also activate PLC which leads to 
an increase of intracellular Ca2+ concentration and formation of DAG (Thelen, 2001). 
The subsequent activation of PKC contributes to the respiratory burst of neutrophils 
and receptor phosphorylation that leads to chemokine receptor desensitization (Li et 
al., 2000; Richardson et al., 1995).  
 
1.2.4.4 Chemokines in acute inflammation 
1.2.4.4.1 Neutrophil and organ damage 
To better understand the functions of chemokines, how neutrophils are involved in the 
development of organ damage during systemic inflammation is first reviewed. In 
SIRS, local infection or inflammation is often accompanied by systemic neutrophil 
activation (Gando et al., 2004). Neutrophils eliminate pathogenic bacteria by 
releasing their large stores of proteolytic enzymes and rapid production of oxygen 
species. If these lytic factors or pro-inflammatory cytokines are released 
extracellularly from tissue-infiltrating neutrophils, they may also contribute to tissue 
damage. Moreover, neutrophils that firmly adhere to the endothelial cells could 
produce microvascular occlusions with subsequent tissue hypoperfusion and hypoxia 
(Brown et al., 2006). Examination of autopsy specimens from patients with multiple 
organ failure reveals localization of neutrophils that varies from sequestration and 
aggregation in renal blood vessels to large-scale tissue infiltration of the lung (Brealey 
  31
and Singer, 2000; Nuytinck et al., 1988; Thijs and Thijs, 1998).In the ARDS, a more 
severe form of acute lung injury that often accompanies SIRS, the intensity of 
neutrophil infiltrates correlates with impaired lung function and with high 
concentrations of neutrophil-derived proteolytic enzymes in the bronchoalveolar 
lavage (Windsor et al., 1993).  
 
1.2.4.4.2 Chemokine and leukocyte migration and activation 
One critical aspect in acute inflammation is to send a big neutrophil army to the 
battlefield. Chemokines play an essential role in this process by establishing a 
concentration gradient to guide neutrophil migration and activating the adhesion 
molecules on the surface of neutrophils. Chemokines are produced and secreted at 
sites of inflammation by resident tissue cells, resident leukocytes, and endothelial 
cells. They are locally immobilized on matrix and cell-surface glycosaminoglycans 
(GAG) as well as on the surface of the overlying endothelium, establishing a 
chemokine concentration gradient surrounding the inflammatory stimulus. 
Chemokines with mutation at GAG binding sites lose their ability to induce leukocyte 
chemotaxis in vivo (Proudfoot et al., 2003). Moreover, chemokine oligomerization on 
GAG may be essential for the activity of some particular chemokines in vivo 
(Proudfoot et al., 2003).  
 
Neutrophil tethering and rolling is mainly mediated by selectin family (P-, E-selectin). 
Selectin-mediated rolling reduces the velocity of circulating neutrophils before they 
can detect chemokines that are immobilized on endothelial cells. When immobilized 
chemokines bind to their receptors, they can activate integrins on the surface of 
neutrophils. However, underlying signaling pathway is not fully understood. Small 
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GTPase RAP1, PI3K, MAPK may be involved in this pathway (Rot and von Andrian, 
2004; Simon and Green, 2005). Integrins are comprised of two subunits. 25 known 
integrins are comprised by 19 alpha subunits and 8 beta subunits. LFA-1(L2) and 
Mac-1 (M2) are the two main integrins that mediate neutrophil firm adhesion and 
transmigration during inflammation. The resting neutrophils constitutively express 
approximately 15,000 Mac-1 and 50,000 LFA-1. In this state, only about 10,000 2 
subunits are in high affinity conformation: about 1000 Mac-1 and 9,000 LFA-1 (Rot 
and von Andrian, 2004). Seconds after chemokine stimulation, the expression and 
affinity of 2 subunits are up-regulated on the neutrophils. Mac-1 expression 
increases about nine-fold up to 140,000, although only 13,000 of them are in high 
affinity conformation (Diamond and Springer, 1993). In contrast, high-affinity LFA-1 
integrins increase to 70,000 (Lum et al., 2002). Within seconds, almost 100% LFA-1 
integrins are activated to mediate a transient reversible adhesion (Hentzen et al., 2000; 
Seo et al., 2001). In contrast, 10 minutes after stimulation only about 10% Mac-1 are 
activated to mediate stable adhesion (Hentzen et al., 2000; Seo et al., 2001). Activated 
2 integrins can bind with endothelial cell surface adhesion molecules such as 
intracellular adhesion molecule-1 (ICAM-1; CD54). This interaction leads to a switch 
from selectin-mediated neutrophil rolling to integrin-mediated firm adhesion and 
extravasation.  
 
1.2.4.4.3 Other functions 
Besides their impact on leukocytes, chemokines may have direct detrimental effect on 
invading pathogens. For example: by screening a total of 30 human chemokines, De 
Yang et al. have identified 17 human chemokines that similar to defensins and exhibit 
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direct antimicrobial activity in vitro (Yang et al., 2003). Moreover, Nakayama et al. 
reveal that chemokines such as MIP-1, MIP-1  and RANTES have a significant 
direct antiviral activity against HSV-1by generating pores in the envelope of HSV-1 
(Nakayama et al., 2006).  
 
1.2.4.5 Pharmacological agents targeting chemokines 
Molecular biology has greatly contributed to the development of chemokine field.  
Due to the triumph of genomic technology and molecular biology, the last two 
decades have witnessed the discovery of many chemokine and their receptors, their 
interaction with invading viruses, and their participation in various diseases. On the 
basis of these studies, recent researches in this field are driven by another approach: 
pharmacology. Various new reagents including small molecules and therapeutic 
antibodies have been developed to manipulate the chemokine system in different 
diseases. The pharmacological approach also provides insights into the accurate 
function of chemokines in vivo.  
 
Animal models and knockout mice are frequently used to study the roles of some 
chemokines and their receptors in human diseases. The initial genetic studies have 
already shown that the chemokines receptors play non-redundant roles in immune 
biology (Carter, 2002). The concern is that in knockout mice, a chemokine or its 
receptor is absent since conception and compensation by an off-target gene might 
occur.  
 
In contrast, pharmacological intervention blocks the chemokines and their receptors 
for a defined time. Chemokine receptors are excellent drug targets because they 
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belong to G-protein-coupled-receptors. In today’s market 30% of drugs are targeting 
at GPCRs (Schwarz and Wells, 2002). A small-molecule antagonist operates either by 
spatially blocking the ligand and receptor interaction (not likely from an energetic 
view) or by holding the receptor in inactivated form (Schwarz and Wells, 2002). 
Figure 1 shows the distribution of published patents for small-molecule inhibitors of 
chemokines receptors. CCR5 and CXCR4 are the targets for AIDS, CCR3 is the main 
target for asthma, CXCR1/2, CCR1 and CCR2 are the targets for various 





Antibodies against chemokine receptors are also in use: MLN12002, an anti-CCR2 
monoclonal antibody from Millennium, is developed for rheumatoid arthritis and the 
anti-CCR5 antibody from HGS is developed for HIV infection (Wells et al., 2006). 
Another form of protein therapeutics is variants of chemokines that act as chemokine 
receptor antagonists. Retention of methionine on RANTES generates a protein Met-
RANTES that inhibits primary cell migration (Proudfoot et al., 1996). Similarly, 
truncated analogues of MCP-1 desensitize the calcium response to MCP-1 and MCP-
3, indicating that N-terminus of chemokine ligands may be essential for the activation 
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of chemokine receptor (Gong and Clark-Lewis, 1995). However, variants of 
chemokines may retain partial agonist activity. For example, Met-RANTES’s partial 
agonist activity leads to the stop of its development as therapeutic agent (Proudfoot et 
al., 1999). 
 
1.2.4.6 Blocking chemokines and their receptors in 
acute pancreatitis and sepsis 
Recent studies begin to reveal that manipulating chemokine system in acute 
inflammatory diseases has valuable therapeutic potential in two clinical conditions: 
acute pancreatitis and sepsis.  
 
The most intensively studied chemokine targets are CXCR1, CXCR2 and their 
ligands probably due to their potent effect on neutrophil migration. A monoclonal 
anti-interleukin 8 antibody (WS-4) has been found to protect against acute lung injury 
in experimental severe acute necrotizing pancreatitis in rabbits. The protection is 
presumably through inhibition of circulating IL-8 and TNF-alpha, and CD11b/CD18 
in lung tissues (Osman et al., 1998). Treatment with a neutralizing antibody against 
CINC, the homologue of the human GRG-, affords significant protection against 
AP-associated lung injury in rats, although it has little effect on caerulein-induced 
pancreatic damage (Bhatia et al., 2000). It has also been reported that anti-MIP-2 
antibody administrated either before or after caerulein partially protected against 
pancreas and lung injury (Pastor et al., 2003). Antileukinate, a hexa-peptide, is an 
inhibitor of binding of CXC chemokines to CXCR2 receptors on human neutrophils. 
Our group’s recent study showed that treatment with antileukinate protected mice 
against AP and associated lung injury (Bhatia and Hegde, 2007). In sepsis, Lin et al 
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have reported that an increased survival (from 58% in controls to 89%) even when the 
inhibitor antileukinate treatment is initiated 24 hours after the induction of sepsis (Lin 
et al., 2005).  Pepducins, GPCR signaling inhibitors that are derived from intracellular 
loops of CXCR1 and CXCR2, reversed the lethal consequence of sepsis, including 
disseminated intravascular coagulation and multi organ failure in mice (Kaneider et 
al., 2005). Moreover, mice deficient in CXCR2 or treated with CXCR2-specific 
antibodies are protected from developing sepsis (Ness et al., 2003). A recent report 
from Reutershan et al shows that besides CXCR2 on neutrophils, endothelial and 
epithelial CXCR2 also play an essential role in LPS-induced neutrophil infiltration 
and lung injury (Reutershan et al., 2006). Murine functional receptor CXCR1 for 
mouse GCP-2 and human interleukin-8 is discovered recently by Fan et al (Fan et al., 
2007). The possible role of this receptor in mouse AP and sepsis models remains 
unknown. Despite these encouraging findings, Reparixin, a specific interleukin-8 
inhibitor in vitro, has no effects on inflammation during endotoxemia (Leitner et al., 
2007). Further clinical studies have to be done to validate CXCR1, CXCR2 or their 
ligands as effective therapeutic targets for these two devastating diseases in humans. 
 
CCR1 is another attractive target. Targeted disruption of a common receptor for MIP-
1α and RANTES, the CCR1 receptor, has been found to be associated with protection 
from pulmonary inflammation secondary to acute pancreatitis in the mouse (Gerard et 
al., 1997). The protection from lung injury associated with decreased levels of TNF-α 
in a temporal sequence indicated that the activation of the CCR1 receptor is an early 
event in SIRS. Our group also demonstrates that treatment with Met-RANTES, a 
peptide-based CCR1 antagonist protect mice against AP-associated lung injury 
although protection against local pancreatic damage was minimal (Bhatia et al., 
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2003). In sepsis, CCR1 knockout mice are significantly protected against CLP-
induced sepsis lethality by promoting cytokine production and enhancing macrophage 
activity (Ness et al., 2004). Although CCR1 deficiency had no effect on the 
inflammatory cell recruitment to the peritoneal cavity (Ness et al., 2004), it has been 
reported that blockage of MIP-1 by antibodies attenuate myeloperoxidase (MPO) 
activity in lung in CLP mice (Speyer et al., 2004). 
 
CCR2 and its primary ligand MCP-1 may play a deleterious role in local pancreatic 
injury during AP. Our group has shown that treatment with bindarit, a blocker of 
MCP-1 synthesis, significantly protected mice against acute pancreatitis as evident by 
attenuated hyperamylasemia, neutrophil sequestration in the pancreas, and pancreatic 
acinar cell injury/necrosis (Bhatia et al., 2005). Studies on the role of CCR2 and 
MCP-1 in sepsis are conflicting. Tsuda et al have reported that MCP-1 induces 
alternatively activated macrophages that weaken antibacterial resistance of SIRS mice 
(Tsuda et al., 2004). Feterowski et al have reported CCR2 blockade by antibody 
enhances IL-10 production and causes impaired bacterial clearance and aggravated 
kidney injury in wild-type mice (Feterowski et al., 2004). Gomes et al have shown 
that MCP-1 deficient mice are more susceptible to sepsis. However, they show that 
MCP-1 deficiency lead to an impaired production of IL-10 and an enhanced 
production of macrophage migration inhibitory factor (Gomes et al., 2006). How to 
manipulate CCR2 or MCP-1 in sepsis to obtain a beneficial effect is still a question to 
be addressed in future work. 
 
Previous studies have revealed that chemokines play a critical role in mediating 
neutrophil infiltration during SIRS and excessive neutrophil infiltration has a harmful 
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effect in tissue injury and organ failure in SIRS. The hypothesis of this study is that 
prevention of neutrophil infiltration by manipulating chemokine system can be a 
logical therapeutic approach for SIRS. The aim of the present study is to discover new 
approaches to manipulate chemokine system during SIRS by animal model of acute 
pancreatitis and sepsis and to examine the consequences of these interventions. 
Therefore, three different strategies were employed: 1. blockage of specific 
chemokine receptor by a small molecule antagonist; 2. depletion of mast cell by 
compound 48/80; 3. administration of exogenous soluble form of CX3C chemokine 
fractalkine. The impacts of each strategy on the outcomes of the diseases and the 
underlying mechanisms by which chemokines influence systemic inflammatory 




II. Materials and methods 
2.1  Induction of acute pancreatitis  
All animal experiments were approved by the Animal Ethics Committee of National 
University of Singapore and carried out in accordance with established International 
Guiding Principles for Animal Research. Male swiss mice (20–25 g) were randomly 
assigned to control or experimental groups using six or more animals for each group. 
In experimental groups animals were given hourly intraperitoneal injections of saline-
containing caerulein (50 μg/kg) for 10 hours. One hour after the last caerulein 
injection, animals were sacrificed by an intraperitoneal (i.p.) injection of a lethal dose 
of pentabarbitone. Harvested heparinized blood was centrifuged and the plasma 
removed and stored at -80°C. Random cross sections of the head, body, and tail of the 
pancreas, and samples of the right lung were fixed in 4% neutral phosphate-buffered 
formalin then embedded in paraffin wax. Samples of pancreas and lungs were frozen 
in liquid nitrogen and stored at -80°C for subsequent measurement of tissue 
myeloperoxidase (MPO) activity. Samples of pancreas and lungs were also used for 
cytokine and chemokine ELISA assay. 
 
2.2  Induction of sepsis  
The previously described model of CLP-induced sepsis was used (Baker et al., 1983; 
Zhang et al., 2006). Male Swiss albino mice (25-30g) were lightly anesthetized with 
the mixture of ketamine and medetomindine (0.75 ml ketamine (100mg/ml) and 1ml 
medetomindine (1mg/ml) dissolved in 8.25ml distilled water) (7.5ml/kg) (Laboratory 
animal center, Singapore) under aseptic conditions. After shaving the abdominal fur 
and applying a topical disinfectant, a small midline incision was made through the 
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skin and peritoneum of the abdomen to expose the cecum. The cecal appendage was 
ligated with Silkam 4/0 thread at 3-5 mm below the ileocecal valve without occluding 
the bowel passage, and then perforated in two locations with a 22-gauge needle distal 
to the point of ligation. After this, a small amount of stool was squeezed out through 
both holes. Finally, the bowel was repositioned, and the abdomen was stitched up 
with sterile Permilene 5/0 thread. Animals with sham operation underwent the same 
procedure without cecal ligation and puncture. 24 hours after the CLP operation, 
animals were sacrificed by an i.p. injection of a lethal dose of pentabarbitone. 
Samples of plasma and tissues were collected. 
 




BX471 (Molecular weight= 434.898 Dalton) ((R)-N-[5-chloro-2-[2-[4-[(4-
fluorophenyl) methyl]-2-methyl-1-piperazinyl]-2-oxoethoxy]phenyl]urea hydrochloric 
acid salt)  (Berlex, Richmond, CA) was dissolved in DMSO 20mg/ml. In acute 
pancreatitis model, BX471 was administered to mice at a dose of 100 mg/kg (in 
62.5ul DMSO) subcutaneously either 30 min before or 1 hour after the first caerulein 
injection. In CLP-induced sepsis model, BX471 was administered to mice at a dose of 
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100 mg/kg (in 62.5ul DMSO) subcutaneously either 30 min before or 30 min after the 
first caerulein injection. 
 
2.4  Mast cell depletion  
Mast cell degranulator compound 48/80 (Sigma Chemical Co., Poole, U.K.) is a 
condensation product of p-methoxyphenethyl methylamine with formaldehyde; it is a 
mixture of low-molecular weight polymers having a degree of polymerization 
between 3 to 6 (Molecular Formula: C11H15NO (monomer) Molecular weight: 153 
(monomer)). Mice were pretreated i.p. every 12 hours for four days, with compound 
48/80 dissolved in PBS and injected at 200 μl/cavity according to the following 
schemes: 1st day, 0.6 mg/kg; 2nd day, 1.0 mg/kg; 3rd day, 1.2 mg/kg; 4th day, 2. 4 
mg/kg as previously described (Carvalho et al., 2005). 24 hours after the last injection 
of compound 48/80, the mice were subject to caerulein injection or CLP operation. 
 
2.5  Fractalkine 
Recombinant FTK (R&D Systems, Minneapolis, MN) was administered to mice at a 
dose of 40g/kg by an intraperitoneal injection 30 min before the first injection of 
caerulein or the CLP operation.  
 
2.6  Water content 
A sample of pancreas was weighed and dried for 72 hours at 60°C and reweighed to 




2.7  Amylase estimation 
Amylase activity was measured by using a kinetic spectrophotometric assay. Plasma 
samples were incubated with the substrate, 4, 6-ethylidene (G7)-p-nitrophenol (G1)-1-
D-maltoheptoside (Sigma, St. Louis, MO) for 4min at 37°C, and absorbance was 
measured every minute for the subsequent 4 min at 405 nm. The change in 
absorbance was used to calculate the amylase activity (Bhatia et al., 2005). 
 
2.8  Myeloperoxidase estimation 
Neutrophil recruitment in lung, pancreas and liver was quantitated by measuring 
tissue MPO activity. Briefly, the tissue samples were homogenized in phosphate 
buffer 20 mmol/l, pH 7.4, centrifuged at 10000 g for 10 min at 4°C and the resulting 
pellet resuspended in phosphate buffer 50 mmol/l, pH 6.0, containing 0.5per cent 
hexadecyltrimethylammonium bromide (Sigma, St. Louis, MO).The suspension was 
subjected to four cycles of freezing and thawing, and further disrupted by sonication 
for 40 s. The sample was then centrifuged at 10000 g for 5 min at 4°C, and the 
supernatant used for the MPO assay. MPO activity was determined as previously 
described using tetramethylbenzidine (Sigma, St. Louis, MO) as the substrate. This 




2.9  Morphological examination 
Paraffin-embedded lung, pancreas and liver samples were sectioned (5μm), stained 
with hematoxylin/eosin, and examined with light microscopy.  
 
2.10 Cytokine and chemokine ELISA assay 
Chemokine levels in lung, pancreas and liver were measured by homogenizing a 
sample of freshly obtained tissue in 1ml phosphate buffer 20mmol/l, pH 7.4, subject it 
to centrifugation and quantitating chemokines in the resulting supernatant. 
Supernatants were assayed for chemokines MCP-1, MIP-1, RANTES and MIP-2 
and cytokines TNF-, IL-1, IL-6 and IL10 using sandwich ELISA, according to the 
manufacturer’s instructions (Duoset kit; R&D Systems, Minneapolis, MN). Briefly, 
primary antibody was aliquoted onto ELISA plates and incubated at room temperature 
over night. Samples and standards were added and incubated for 2 hours, the plates 
were washed, and a biotinylated secondary antibody was added and incubated for 2 
hours. Plates were washed again, and streptavidin bound to horseradish peroxidase 
was added for 20 min. After a further wash, tetramethylbenzidine was added for color 
development, and the reaction was terminated with 2M H2SO4. Absorbance was 
measured at 450 nm. 
 
2.11 Immunohistochemistry 
Lung, pancreas and liver samples were isolated and immediately fixed in formalin 
(10%, buffered at pH 7.4) for 12 hours. The fixed tissues were then embedded in 
paraffin and kept until use. Paraffin sections (5 μm) were dewaxed, hydrated, washed, 
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and endogenous peroxidase activity was quenched with 0.3% H2O2 for 15 min before 
staining. Antigen retrieval was performed by incubating the slides in pre-heat citrate 
buffer (PH=6.0, 95°C) for 15 minutes. This was followed by 2 hours incubation with 
corresponding primary antibody at optimal dilution. After that, the sections were 
incubated in corresponding peroxidase-conjugated secondary antibody at optimal 
dilution for 30 min (Table 2). Finally, the slides were treated with chromogen 3,3’-
diaminobenzidine for 5 min, rinsed, counterstained with haematoxylin, dehydrated in 
Histoclear and coverslipped. Negative controls were included by replacing the 
primary antibody with PBS. All incubations and washes were performed with PBS 
(3х5min), and carried out at room temperature (25°C), unless otherwise stated. The 




Antigen Primary Antibody Optimal 
dilution 
Secondary antibody Optimal 
dilution 
ICAM-1 Rat anti-mouse ICAM-1 
monoconlonal antibody 
(Chemicon) 
1:300 Goat anti-rat 
IgG:HRP (Serotec) 
1:50 
P-selectin Goat anti-mouse P-Selectin 
IgG (Biovision) 




E-selectin Rabbit anti-E-Selectin 
polyclonal antibody 
(Biovison) 





2.12 Reverse transcriptase- polymerase 
chain reaction 
Total RNA from lung, pancreas and liver was extracted with Trizol (R) reagent 
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol. The 
concentration of isolated nuclei acids was determined spectrophotometrically by 
measuring the absorbance at 260nm and the integrity was verified by ethidium 
bromide staining of 18S and 28S rRNA bands on a denaturing agarose gel. All 
samples were thereafter stored at -80 °C until required. 1μg RNA was reversely 
transcribed using iScript(TM) cDNA Synthesis Kit (Biorad, Hercules, CA, USA) at 
25°C for 5 minutes, 42°C for 30 minutes, followed by 85°C for 5 minutes. The cDNA 
was used as a template for PCR amplification by iQ(TM) Supermix (Biorad, 
Hercules, CA, USA). The sequences of the primers were as follows:  
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 ICAM-1 (GeneID: 15894) sense 5’-CAACTGGAAGCTGTTTGAGCTG-3’ 
(Position: 219) and antisense 5’-TAGCTGGAAGATCGAAAGTCCG-3 
(Position: 655), product size: 437bp;  
 P-selectin (GeneID: 20344) Sense: 5’-TACGAGCTGGACGGACCCG-3’ 
(Position: 709) and antisense: 5’-GGCTGGCACTCAAATTTACAGC-3’ 
(Position: 890), product size: 182bp; 
 E-selectin (GeneID: 20339) Sense: 5’-TCAACTTGAGTGCACATCTCAGG-
3’ (Position: 1437) and antisense: 5’-TGATTGAAGGCTTTGGCAGCT-3’ 
(Position: 1824), product size: 388bp; 
 FTK (GeneID: 20312) sense 5’-ACAGACGCTTCTGTGCTGA-3’ (Position: 
209) and antisense 5’ -TCCAAAGCAAGGTCTTCCA-3’ (Position: 419), 
product size: 211bp (Cook et al., 2001);  
 CX3CR1 (GeneID: 13051) sense 5’-GGCCTGTTATTTGGGCGACAT-3’ 
(Position: 60) and antisense, 5’-TGGGGTGACGCCACTAAGAT-3’ 
(Position: 494), product size: 435bp (Barlic et al., 2003);  
 18S (GeneID: 19791) sense, 5’-GTAACCCGTTGAACCCCATT-3’ (Position: 
1577) and antisense, 5’-CCATCCAATCGGTAGTAGCG-3’ (Position: 1727), 
product size, 151bp.  
PCR products were electrophoresed through 1.5% agarose gels containing 0.5 µg/ml 
ethidium bromide (Bio-Rad) and visualized by the UVP® bioimaging system (UVP, 
Upland, CA, USA). The intensity of bands was analyzed using LabWorksTM Image 
Analysis software (UVP). 18S was used as an internal control. Densitometry results 
from all PCR products were normalized to 18S. 
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2.13 Isolation of peritoneal mast cells  
Peritoneal mast cells are isolated as previously described with minor modification 
(Eastmond et al., 1997). Peritoneal cells were obtained by ex vivo lavage of mice with 
20 ml of HBSS (Life Technologies, Paisley, Scotland). The cells were centrifuged at 
400 g for 5 min. The pellets were pooled and resuspended in 1ml 0.8% NH4CL and 
stand for 5 min to remove red blood cell. An additional 14 ml of HBSS was added. 
Centrifuge at 400 g for 5 min. The pellet was re-suspended in 5ml HBSS and washed 
by centrifuging at 400g 5 min. The pellet was resuspended in 8ml of 70% isotonic 
Percoll solution (Sigma Chemical Co., Poole, U.K.). Complete DMEM (cDMEM; 
DMEM (Life Technologies) supplemented with 10% FBS (HyClone, Logan, UT, 
USA), 20uM HEPES 2 mM glutamine, 10 units/ml penicillin, and 10 mg/ml 
streptomycin (Invitrogen)) (2 ml) was laid on top, and the cells were centrifuged at 
580 g for 15 min. Mast cells were recovered from the pellet, washed, and resuspended 
in cDMEM. Add 10ul cell suspension to 10ul toluidine blue solution and incubate at 
37 C for 10min. Count the total number of mast cells using a hemacytometer. 
 
2.14 Intravital microscopy 
The microscopic setup used has been described in detail previously (Lau and Bhatia, 
2007; Zhang et al., 2007). Male Swiss mice (25–30 g) were anesthetized initially with 
the mixture of ketamine and medetomindine [0.75 ml ketamine (100 mg/ml) and 1 ml 
medetomindine (1 mg/ml) (Laboratory animal center, Singapore), dissolved in 8.25 
ml distilled water; 7.5 ml/kg]. A midline, abdominal incision was made, and the 
animals were placed in a supine position. A segment of the mid-jejunum was 
exteriorized through the abdominal incision, and all exposed tissue was covered with 
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saline-soaked gauze to minimize tissue dehydration. The mesentery was placed 
carefully over a water chamber. The temperature of the chamber was maintained at 
37°C. The mesentery was suffused with warm, bicarbonate-buffered saline (pH 7.4). 
An intravital microscope (Nikon, Japan) with a 20 objective lens and a 10 eyepiece 
was used to observe the mesenteric microcirculation. For visualization of leukocytes, 
the fluorescent marker rhodamine 6G (Sigma Chemical Co., Poole, U.K.) was 
injected intravenously (i.v.) as a single bolus of 0.15 mg/kg body weight, immediately 
prior to each measurement. Epi-illumination was achieved with a variable HBO 
mercury lamp. A video camera mounted on the microscope projected the image onto a 
color monitor, and the images were recorded for playback analysis. Three to five 
venules (20-40 m in diameter) were selected in each experiment, and to minimize 
variability, the same section of each venule was observed throughout the experiment. 
The number of adherent and rolling leukocytes was determined during playback of 
video images. 
 
The interaction of leukocytes with the luminal surface of the venular endothelium was 
investigated 16 hours after CLP surgery. Leukocytes were considered adherent to 
venular endothelium if they remained stationary for 30 s or more within a given 
100m vessel segment. Rolling leukocytes were defined as those leukocytes, which 
moved at a velocity less than two-thirds of that of erythrocytes in the same vessel. 
Leukocyte rolling velocity was determined from the time required for a leukocyte to 




Data are expressed as the mean±SE. In all figures, vertical bars denote SE. The 
significance of changes was evaluated by using t-test when comparing two groups. 
The significance of changes was evaluated by using ANOVA when comparing three 
or more groups. If ANOVA indicated a significant difference, the data were analyzed 
by using Tukey’s method as a post hoc test for the difference between groups. A P 
value of <0.05 was considered to indicate a significant difference. 
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III. Treatment with BX471, a small 
molecule antagonist of CCR1, protects 
against systemic inflammation in mouse 
models of acute pancreatitis and sepsis 
3.1 Introduction 
Acute pancreatitis begins with premature activation of intracellular zymogens and 
local production of cytokines and chemokines (Nagar and Gorelick, 2004).  
Subsequent inappropriate activation of immune system may increase the severity of 
both the local injury and the systemic complications such as lung injury. One potential 
therapy approach for acute pancreatitis is to manipulate the activation and recruitment 
of neutrophils because early studies have already shown that depletion of circulating 
neutrophils with anti-neutrophil serum reduces both pancreatic and distant organ 
damage in experimental acute pancreatitis (Bhatia et al., 1998; Han et al., 1996; Inoue 
et al., 1995). 
 
CCR1 chemokine receptor is a potential therapeutic target for acute pancreatitis. 
Targeted disruption of CCR1 receptor has been found to be associated with protection 
from pulmonary inflammation secondary to acute pancreatitis in the mouse (Gerard et 
al., 1997). It has also been shown that treatment with Met-RANTES, a peptide-based 
CCR1 antagonist, protect mice against AP-associated lung injury although protection 
against local pancreatic damage was minimal (Bhatia et al., 2003). However, Met-
RANTES antagonize CCR1 as well as CCR5 (Proudfoot et al., 1999). Moreover, it 
preserves partial agonist activity. Therefore, a most specific and potent antagonist 
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should be employed to fully reveal the role of CCR1 in pathogenesis of acute 
pancreatitis.  
 
Sepsis is a complex clinical syndrome resulting from a harmful host response to 
infection, which frequently occurs after hemorrhage, trauma, burn, or abdominal 
surgery (Cohen, 2002). The host response to pathogens in sepsis is characterized by 
infiltration of specific leukocyte populations especially neutrophils into host tissues.  
 
CCR1 is expressed on neutrophils and is up-regulated on neutrophils in murine CLP 
induced sepsis model (Speyer et al., 2004). Its main ligands include MIP-1α and 
RANTES. It has already been shown that MIP1- enhances the protective innate 
immune response against sepsis by activating macrophages, while RANTES triggers 
the overproduction of pro-inflammatory cytokines and chemokines, resulting in 
aggravated injury and mortality following sepsis (Ness et al., 2004; Takahashi et al., 
2002).  The first attempt to study the role of CCR1 in sepsis has shown that CCR1 
knockout mice are significantly protected against CLP-induced lethality (Ness et al., 
2004). However, it is possible that the protective effect of CCR1 deficiency in sepsis 
may be due to its influence on the developmental process of macrophages (de Wynter 
et al., 2001; Matsukawa et al., 2006).  
 
Therefore, a small-molecule non-peptide CCR1 antagonist was employed in the 
present study to demonstrate the role of CCR1 during acute pancreatitis and sepsis. 
BX471 is a potent non-peptide CCR1 antagonist for both human and mouse. It has 
been reported that BX 471 displaces the CCR1 ligands, MIP-1α, RANTES, and MCP-
3, with high affinity and is a potent functional antagonist based on its ability to inhibit 
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a number of CCR1-mediatede effects including Ca2+ mobilization and leukocyte 
migration. In addition, BX471 demonstrated a greater than 10,000-fold selectivity for 
CCR1 compared with 28 different GPCRs (Ribeiro and Horuk, 2005).  
 
The aim of the present study was to evaluate the effect of prophylactic and therapeutic 
treatment with BX471 on experimental acute pancreatitis and sepsis in the mouse and 




3.2.1 BX471 treatment in caerulein-induced 
acute pancreatitis 
Different dosage of BX471 has been used in different rodent disease models in 
previous studies. Treatment with BX471 (50mg/kg) at 8 hour intervals attenuates 
renal fibrosis after unilateral ureter ligation in mouse (Anders et al., 2002). To choose 
an optimum dose for BX471 treatment in caerulein-induced acute pancreatitis model, 
dose-dependent effect of BX471 on lung MPO activity was studied. The result has 
shown that BX471 treatment at 100mg/kg was more effective than 50mg/kg and 
30mg/kg in attenuating neutrophil infiltration in lungs as shown in Figure 3. 




Values  are  mean±SE  for  six  animals  in  each  group.  Pbo:  placebo;  BX:  BX471;  CAE: 
caerulein. Control: normal mice; Pbo+CAE, placebo followed by caerulein; (BX100)+CAE, 
BX471 (100mg/kg) followed by caerulein; (BX50)+CAE, BX471 (50mg/kg) followed by 




BX471 was dissolved in 62.5ul DMSO and was administered to mice at a dose of 100 
mg/kg subcutaneously. To determine the effect of DMSO as placebo on acute 
pancreatitis, plasma amylase activity, pancreatic MPO activity and lung MPO activity 
were measured.   As shown in Figure 4, in animals treated with placebo and caerulein, 
DMSO has no significant effect on acute pancreatitis as manifested by amylase 





mean±SE  for  six  animals  in  each  group. Pbo: placebo; CAE:  caerulein.  Control:  normal 




Effect of BX471 treatment on local pancreatic injury was first investigated. 
Hyperstimulation of the pancreas by i.p. administration of caerulein at a dose of 50 
μg/kg hourly for 10 hours resulted in acute pancreatitis in mice. This was confirmed 
by an increase in plasma amylase (Figure 5 a), an increase in pancreatic water content 
as a measure of pancreatic edema (Figure 5 b), and an increase in pancreatic MPO 
activity as a measure of neutrophil infiltration (Figure 5 c) in mice treated with 
placebo and caerulein compared with control mice. In animals administered BX471, 
either 30 minutes before starting caerulein administration or 1 hour after the first 
injection of caerulein, plasma amylase levels and pancreatic water content were 
unchanged compared with those in animals treated with caerulein and placebo. 
However, MPO activity in the pancreas was reduced in both groups of mice treated 
with BX471, indicating that BX471 treatment attenuated neutrophil infiltration in 
pancreas. Sections examined for pancreatic injury/necrosis were characterized by (i) 
edema and destruction of histoarchitecture of whole or parts of the acini for pancreas; 
and (ii) inflammatory cell infiltration into the necrotic areas in pancreatic tissue. 
Histological examination of pancreatic sections confirmed a lack of effect of BX471 
treatment on local acute pancreatitis as shown in Figure 6. Taken together, these 
observations indicate that BX471 treatment has no significant protective effect against 
local pancreatic injury, which is consistent with previous findings in CCR1 receptor 





(a)  plasma  amylase;  (b)  pancreatic  water  content;  and  (c)  pancreatic  MPO  activity. 
Values  are mean±SE  for  eight  to  ten  animals  in  each  group.  Pbo: placebo; BX: BX471; 
CAE: caerulein. Control: normal mice; Pbo+CAE, placebo followed by caerulein; BX+CAE, 






Figure  6  Morphological  changes  in  pancreas  with  or  without  treatment  with 
BX471  
(a)  Control,  normal  pancreas;  (b)  Caerulein‐induced  acute  pancreatitis;  placebo 
treatment  30  min  before  the  first  caerulein  injection;  (c)  Caerulein‐induced  acute 
pancreatitis; BX471 treatment 30 min before the first caerulein injection; (d) Caerulein‐





It is well-established that in caerulein-induced acute pancreatitis model, local 
pancreatic injury was followed by a secondary respiratory distress syndrome in lung. 
It was observed that lungs from mice treated with caerulein had increased levels of 
MPO activity in comparison to control animals, suggesting neutrophil infiltration into 
lungs as a result of systemic inflammatory response following local acute pancreatitis 
(Figure 7). Administration of BX 471 either 30 minutes before or 1 hour after the first 
caerulein injection significantly reduced lung MPO levels in caerulein-treated 
animals. The morphological changes in lung following induction of acute pancreatitis 
and the protective effect of BX471 treatment are shown in Figure 8. The lung sections 
from acute pancreatitis mice exhibited characteristic signs of lung injury, which 
included interstitial edema, alveolar thickening, and severe leukocyte infiltration in 
the interstitium and alveoli. Prophylactic and therapeutic treatment with BX471 
attenuated these signs of inflammation. Taken together, these observations indicate 







Values  are mean±SE  for  eight  to  ten  animals  in  each  group.  Pbo: placebo; BX: BX471; 
CAE: caerulein. Control: normal mice; Pbo+CAE, placebo followed by caerulein; BX+CAE, 











treatment  30  min  before  the  first  caerulein  injection;  (d)  Caerulein‐induced  acute 





To examine the effects of BX471 treatment on chemokines in acute pancreatitis, MIP-
1 and MCP-1 levels in lung and pancreas were determined by ELISA. Treatment 
with BX471 resulted in an up-regulation of MIP-1 levels in lung (Figure 9), 
presumably because it is unable to bind its main receptor CCR1. Moreover, treatment 
with BX471 resulted in a significant decrease of MCP-1 levels in both lung and 
pancreas compared with placebo treated groups (Figure 9). These findings suggest 
that blocking CCR1, a CC chemokine receptor, may affect the expression of some CC 




are  mean±SE  for  eight  to  ten  animals  in  each  group.  Pbo:  placebo;  BX:  BX471;  CAE: 
caerulein.  Control:  normal  mice;  Pbo+CAE,  placebo  followed  by  caerulein;  BX+CAE, 




Previous in vitro experiments have shown that there may be an interaction between 
CCR1 and adhesion molecules (Wan et al., 2003). In an attempt to determine the 
effect of BX471 treatment on adhesion molecules during acute pancreatitis, ICAM-1, 
P-selectin and E-selectin mRNA expression was measured by RT-PCR. The results 
have shown that acute pancreatitis resulted in a significant up-regulation of ICAM-1, 
P-selectin and E-selectin gene expression compared with control group in both lung 
and pancreas (Figure 10 and Figure 11). Treatment with BX471 led to a down-
regulation of these adhesion molecules at mRNA level compared with placebo-treated 
groups in both lung and pancreas as shown in Figure 10 and Figure 11. 
 
Protein expression and localization of ICAM1, P-selectin and E-selectin in lung and 
pancreas was investigated using immunohistochemistry. In lung P-selectin and E-
selectin were localized on vascular surface. In contrast, ICAM-1 was detected 
throughout the alveolar epithelium and endothelial cells (Figure 12). In pancreas, 
ICAM-1, P-selectin and E-selectin were all localized on vascular surface (Figure 13).  
An evident increase in ICAM-1, P-selectin and E-selectin immunoreactivity in both 
lung and pancreas was observed during acute pancreatitis. Treatment with BX471 led 
to a down-regulation of ICAM-1, P-selectin and E-selectin immunoreactivity in both 











BX:  BX471;  CAE:  caerulein.  Control:  normal  mice;  Pbo+CAE,  placebo  followed  by 







(a) Results  shown are  representative gel photographs showing  the RT‐PCR analysis of 
ICAM‐1, P‐selectin, E‐selectin and 18s mRNA in pancreas. (b) The histogram represents 
the  ratio of  ICAM‐1:18s,  P‐selectin:18s  and E‐selectin:18s  in  each  group,  expressed  as 
fold  increase  over  control.  Values  are  mean±SE  for  six  animals  in  each  group.  Pbo: 
placebo; BX: BX471; CAE:  caerulein. Control: normal mice; Pbo+CAE, placebo  followed 






(a)‐(c)  Immunohistochemistry  of  ICAM‐1  in  lung;  (d)‐(f)  Immunohistochemistry  of  P‐
selectin  in  lung;  (g)‐(i)  Immunohistochemistry  of  E‐selectin  in  lung.  (a),  (d)  and  (g) 
control mice; (b), (e) and (h) Caerulein‐induced acute pancreatitis; placebo treatment 30 
min  before  the  first  caerulein  injection;(c),  (f)  and  (i)  Caerulein‐induced  acute 







P‐selectin  in pancreas;  (g)‐(i)  Immunohistochemistry of E‐selectin  in pancreas.  (a),  (d) 
and  (g)  control  mice;  (b),  (e)  and  (h)  Caerulein‐induced  acute  pancreatitis;  placebo 







3.2.2 BX471 Treatment in CLP-induced sepsis 
CLP induced systemic inflammation was indicated by the lung and liver MPO 
activity, a marker of neutrophil infiltration. As expected, lung MPO activity was 
significantly increased 24 hours after CLP when compared with control and sham 
operated groups. Similarly in liver, a significant elevation in MPO activity was 
observed 24 hours after CLP. Administration of BX471 either 30 minutes before 
(prophylactic) or 30 minutes after (therapeutic) CLP significantly reduced lung and 
liver MPO levels in animals (Figure 14).  Histology examination showed the 
morphological changes in lung and liver following induction of sepsis. The lung 
sections from placebo treated mice with CLP operation exhibited characteristic signs 
of lung injury, which included interstitial edema, alveolar thickening, and severe 
leukocyte infiltration in the interstitium and alveoli (Figure 15). In liver sections, 
hepatocyte swelling, slight hepatocyte necrosis and neutrophil infiltration could be 
easily observed (Figure 16). The protective effect of BX471 treatment was show in 































To examine the effects of BX471 treatment on chemokines in acute pancreatitis, 
levels of MIP-1, a main ligand of CCR1, in lung and pancreas were determined by 
ELISA. The results have shown that BX471 treatment resulted in up-regulation of 
MIP-1 protein levels in lung 24 hours after CLP (Figure 17), presumably because it 
is unable to bind its main receptor CCR1. This result is similar to the finding in acute 










Previous in vitro studies have shown that there may be an interaction between CCR1 
and adhesion molecules (Wan et al., 2003). In an attempt to determine the effect of 
BX471 treatment on adhesion molecules during sepsis, ICAM-1, P-selectin and E-
selectin mRNA expression was measured by RT-PCR. The results have shown that 
CLP induced sepsis resulted in significant up-regulation on ICAM-1, P-selectin, and 
E-selectin gene expression compared with control group in lung and liver (Figure 18 
and Figure 19). Treatment with BX471 led to a down-regulation of these adhesion 
molecules at mRNA level compared with placebo-treated groups in lung and liver as 
shown in Figure 18 and Figure 19. 
 
Protein expression and localization of ICAM-1, P-selectin and E-selectin in lung and 
liver was investigated using immunohistochemistry. In lung P-selectin and E-selectin 
was localized on vascular surface; however, ICAM-1 was detected throughout the 
alveolar epithelium and endothelial cells. In liver ICAM-1, P-selectin and E-selectin 
was mainly localized on vascular surfaceFigure 20 and Figure 21. An increase in 
ICAM-1, P-selectin and E-selectin protein expression in lung and liver during sepsis 
was observed. Treatment with BX471 led to a down-regulation of ICAM-1, P-selectin 








(a) Results  shown are  representative gel photographs showing  the RT‐PCR analysis of 
ICAM‐1, P‐selectin, E‐selectin and 18s mRNA in lung. (b) The histogram represents the 
ratio of  ICAM‐1:18s, P‐selectin:18s and E‐selectin:18s  in each group, expressed as  fold 
increase over control. Values are mean±SE for six animals in each group. Pbo: placebo; 
BX:  BX471;  Pbo+CLP,  placebo  followed  by  CLP;  BX+CAE,  BX471  followed  by  CLP; 









ratio of  ICAM‐1:18s, P‐selectin:18s and E‐selectin:18s  in each group, expressed as  fold 
increase over control. Values are mean±SE for six animals in each group. Pbo: placebo; 
BX:  BX471;  Pbo+CLP,  placebo  followed  by  CLP;  BX+CAE,  BX471  followed  by  CLP; 





(a)‐(c)  Immunohistochemistry  of  ICAM‐1  in  lung;  (d)‐(f)  Immunohistochemistry  of  P‐
selectin  in  lung;  (g)‐(i)  Immunohistochemistry  of  E‐selectin  in  lung.  (a),  (d)  and  (g) 
control mice; (b), (e) and (h) CLP‐induced sepsis; BX471 treatment 30 min before CLP 
procedure;(c),  (f)  and  (i)  CLP‐induced  sepsis;  BX471  treatment  30  min  after  CLP 






(a)‐(c)  Immunohistochemistry  of  ICAM‐1  in  lung;  (d)‐(f)  Immunohistochemistry  of  P‐
selectin  in  lung;  (g)‐(i)  Immunohistochemistry  of  E‐selectin  in  lung.  (a),  (d)  and  (g) 
control mice; (b), (e) and (h) CLP‐induced sepsis; BX471 treatment 30 min before CLP 
procedure;(c),  (f)  and  (i)  CLP‐induced  sepsis;  BX471  treatment  30  min  after  CLP 








When CC and CXC chemokines were first identified, it was believed that CXC 
chemokines mediated neutrophil migration while CC chemokine mediated monocyte 
migration. Later studies show that this narrow definition is not correct. Recent studies 
begin to reveal that CC chemokines also play an active role in the progress of acute 
pancreatitis. In the mouse, MIP-1α is a potent mediator for neutrophils recruitment 
and activation (Standiford et al., 1995).  In human, CCR1 is present and up-regulated 
in isolated human neutrophils after treatment with interferon-γ or granulocyte 
macrophage colony-stimulating factor and subdermal injection of MIP-1 leads to 
neutrophil as well as monocyte influx in human volunteers suggests that CC 
chemokines may also be involved in neutrophil trafficking in humans (Bonecchi et 
al., 1999; Cheng et al., 2001; Lee et al., 2000). CCR1 deficient mice were first 
employed to study the role of CCR1 in acute pancreatitis; and CCR1 antagonist Met-
RANTES shows a similar protective effect against lung injury (Bhatia et al., 2003; 
Gerard et al., 1997). In the present study, CCR1 is blocked by a non-peptide specific 
CCR1 antagonist BX471 in acute pancreatitis model. Blockage of CCR1 leads to the 
attenuation of MPO activity in both pancreas and lungs, indicating that CCR1 may 
play a critical role in mediating neutrophil infiltration in AP.  
 
Despite the attenuated neutrophil infiltration, local pancreatic injury is not 
significantly attenuated after the treatment with BX471 judging by amylase activity, 
histology and water content. These findings suggest that many early events such as 
zymogen activation, intracellular calcium elevation that contributes to local pancreatic 
injury may not be affected by blockage of CCR1. However, remote lung organ 
damage is significantly attenuated after treatment of BX471, suggesting that CC 
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chemokines that bind to CCR1 may act as critical systemic inflammatory mediators 
but not essential local inflammatory mediators during AP.      
 
Although it was reported that CCR1 deficiency had no effect on the inflammatory cell 
recruitment to the peritoneal cavity, our data have shown that blockage of CCR1 by 
BX471 attenuates MPO activity in both lung and liver tissues, which is consistent 
with previous report that blockage of MIP-1, a main ligand of CCR1, by antibodies 
attenuates the increase of MPO activity in lung in CLP mice, indicating that CCR1 
play a key role in controlling neutrophil infiltration into the tissues (Ness et al., 2004; 
Speyer et al., 2004). As activated neutrophils release protease and reactive oxygen 
species which lead to host tissue damage during sepsis, down-regulation of 
neutrophils infiltration may contribute to the protective effect in lung and liver in 
BX471 treated groups as shown in histology examination.   
 
RANTES and MIP-1 are the two main ligands for CCR1 in vivo. Besides CCR1, 
RANTES can also bind to other CC chemokine receptors including CCR3 and CCR5 
and MIP-1 can binds to CCR3. Recent work by our lab and other researchers has 
shown that CC chemokine MCP-1 may play a pivotal role in the pathological 
mechanism of acute pancreatitis (Bhatia et al., 2005). Therefore, the effect of CCR1 
blockage by BX471 on various chemokines in lung and pancreas was investigated. 
Our data show that blocking CCR1 can increase the expression of MIP-1 in lung in 
both acute pancreatitis and sepsis. Similarly it has been reported that CCR2b 
knockout mice have higher systemic MCP-1, a ligand for CCR2b, levels compared 
with wild-type mice in acute pancreatitis. Interesting, blocking CCR1 leads to a 
down-regulation of MCP-1 levels in both lungs and pancreas in acute pancreatitis. 
  79
These findings suggest that blocking CCR1 may not only increase the levels of its 
ligand MIP-1, but also influence the levels of other CC chemokine ligand.  There are 
some evidences suggesting the relationship between CCR1 and other chemokines’ 
expression by CCR1 knockout mice and by CCR1 antagonist in other models. In CLP 
induced sepsis model, MIP-2 levels in peritoneal lavage fluid and MCP-1 levels in 
serum are attenuated in CCR1 knockout mice compared with wide-type mice 24 hours 
after CLP procedure (Ness et al., 2004). Treatment with BX471 also leads to a down-
regulation of MCP-1 and RANTES at protein levels in the model of progressive 
immune complex glomerulonephritis in autoimmune MRLlpr/lpr mice (Anders et al., 
2004). The underlying mechanisms are not clear yet.  
 
In acute inflammation, endothelial cells are active responders to inflammatory 
stimulus by producing cytokines and chemokines and expressing cellular adhesion 
molecules (Szekanecz and Koch, 2004). Therefore, in the present study, the 
interaction between CCR1 and cellular adhesion molecules that are expressed on the 
vascular endothelium was investigated. Our results show that blockage of CCR1 by 
BX471 lead to a down-regulation of P-selectin, E-selectin and ICAM-1 at both 
mRNA and protein levels in both models. The underlying mechanism is not clear yet. 
However, it has been observed that challenge with MIP-1 and MCP-1 has no effect 
on the expression of P-selectin on endothelial cells in vitro, indicating that CC 
chemokines may not be capable of directly activating endothelial cells (Wan et al., 
2003). Recent studies have suggested that mast cells may play an intermediated role 
in chemokine-induced neutrophils recruitment in vivo by releasing TNF- to activate 
endothelial cells (Wan et al., 2003; Wang and Thorlacius, 2005). It is evident that 
other inflammatory cells, including macrophages, lymphocytes, adherent neutrophils 
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and other mediators, for example IL-1 and leukotrienes, may also be involved in this 
complex interaction between CC chemokines, endothelial cells and neutrophil 
recruitment. Down-regulation of the adhesion molecules on endothelial cells by 
BX471 may further contribute to the attenuation of neutrophil recruitment and 
activation.  
 
Unlike most CCR1 antagonists that can only antagonize human CCR1 but not rodent 
CCR1, BX471 is a potent CCR1 antagonist in human, rat and mouse. Its cross-species 
activity makes it an appealing tool in animal models with therapeutic potential in 
humans. BX471 has show a therapeutic effect in several animal models including 
multiple sclerosis, progressive kidney disease and organ transplant rejection (Ribeiro 
and Horuk, 2005). BX471 is now moving from the laboratory bench side to the clinic 
bed side. A phase 2 clinical study has been initiated to evaluate its safety and efficacy 
as a therapeutic agent for multiple sclerosis and psoriasis (Horuk, 2005). As BX471 
shows a protective effect against lung injury in animal model of acute pancreatitis and 
lung and liver injury in the CLP model of sepsis, in the future, this antagonist may 
also be useful for evaluating the role of CCR1 during acute pancreatitis and sepsis in 
humans.  
 
In summary, the effect of a CCR1 antagonist BX471 on pancreatic and lung damage 
was examined using a model of acute pancreatitis induced by the pancreatic 
secretagogue caerulein. Treatment with BX471 results in significant protection against 
lung damage, as measured by lung MPO levels and histology. Treatment with BX471 
does not appear to affect pancreatic damage although it significantly attenuated 
pancreatic MPO levels. This is in agreement with previous studies with CCR1 
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knockout mice. It has been shown that blocking CCR1 leads to a down-regulation of 
P-selectin, E-selectin and ICAM-1 in both lung and pancreas suggesting there is a 
complex interaction between chemokines and adhesion molecules on endothelial cells 
in acute pancreatitis although the underlying mechanism is not fully understood. Most 
patients of acute pancreatitis seek medical attention within the 12-18 hours after the 
onset of the pain. The effect of distant organ damage in patients of severe attack only 
becomes apparent over the following 48 hours. Therefore, there is a therapeutic 
window between hospital presentation and the development of distant organ 
dysfunction (Bhatia et al., 2000). It is encouraging to notice that therapeutic 
administration of BX471 1 hour after the induction of acute pancreatitis is as effective 
as prophylactic administration 30 minutes before. This suggests that this antagonist 
might be of clinical use to prevent lung injury in patients either before the onset of 
acute pancreatitis or even after the onset of acute pancreatitis (Proudfoot, 2002). 
 
The effect of a CCR1 antagonist BX471 on systemic inflammatory response was 
examined using a model of sepsis induced by CLP operation. Treatment with BX471 
results in a significant protection against lung and liver damage, as shown by MPO 
levels and histology. It has also been shown that blocking CCR1 leads to a down-
regulation of P-selectin, E-selectin and ICAM-1 in both lung and liver, suggesting 
there is a complex interaction between chemokines and adhesion molecules on 
endothelial cells in sepsis although the underlying mechanism is not fully understood. 
Despite more than twenty years of extensive study, sepsis is still the main causes of 
death in intensive units. Blockage of chemokine receptors by specific antagonist 
might be a promising strategy for treatment of sepsis (Proudfoot, 2002). It is known 
that the onset and progression of sepsis to multi-organ dysfunction develops in hours 
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to days in CLP models, while this process occurs in days to weeks in human patients. 
It has been reported that in rat the activation of p38 MAPK is increased in liver 30 
minutes after CLP procedure indicating rapid host response against infection in rodent 
CLP models (Maitra et al., 2003).  30 minutes after CLP procedure downstream 
pathways have already been activated and administration of BX471 at this time point 
has shown protective effect in our study. Future work will be undertaken to assess the 
therapeutic potential of BX471 at later time points in this preclinical model and, in the 






IV. Mast cell depletion attenuates 
chemokine production in caerulein-
induced acute pancreatitis and CLP-
induced sepsis 
4.1  Introduction 
Mast cells are resident in tissues throughout the body and are most common at the 
sites that are exposed to external environment, such as skin, the airway and the 
intestine. Mast cells have been extensively studied as the main effector cells in the 
elicitation of allergic response. Emerging evidence begin to reveal that it may play a 
critical role in innate immune responses as well.  
 
Mast cells can be activated by a variety of stimuli including invading pathogens 
during innate immune responses. Some specific cell-surface receptors on mast cells 
can directly recognize complementary ligands on microorganism surface. For 
example, CD48 on mast cells can specifically bind FimH which is expressed by E. 
coli and other enterobacteria (Malaviya et al., 1999). Moreover, a wide variety of 
TLRs are expressed on mast cells and mediate mast cell activation events in response 
to bacterial, fungal and viral associated signals (Supajatura et al., 2002). Besides 
direct activation, the indirect activation of mast cells is also crucial for the host 
response to a wide range of organisms. When microbes are coated with complement 
component, they can be indirectly recognized by complement receptors on mast cells 
(Nilsson et al., 1996; Prodeus et al., 1997). When IgG or IgE is produced, it can be 
recognized by Fc receptors on mast cells (Segal et al., 1977; Woolhiser et al., 2001). 
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Moreover, cytokine and chemokine microenvironment is able to modulate the 
response of mast cells (Marshall, 2004).  
  
To elicit protective innate immune responses, mast cell can selectively produce and 
release at least three main classes of mediators: pre-formed granule-associated 
mediators, newly generated lipid mediators; and a variety of cytokines and 
chemokines (Mekori and Metcalfe, 2000). The location of mast cells, which is often 
closely associated with blood vessels, allows some of these mediators to enhance 
leukocyte recruitment. TNF- and IL-1, for example, are capable of increasing 
vascular permeability and enhancing adhesion molecule expression on endothelial 
cells. Other mediators like leukotriene B4, mast-cell-derived proteases and 
chemokines are potent chemoattractant for specific types of leukocytes, such as 
neutrophils and macrophages.  Previous studies have shown that mast cells may be 
important sources of multiple chemokines including: IL-8, I-309, MCP-1, MIP-1, 
MIP-1, RANTES, and ENA78 (Lukacs et al., 1998; Selvan et al., 1994).  
 
The role of mast cells in the pathogenesis of acute pancreatitis and sepsis is not fully 
understood.  In this study, the effect of mast cell depletion by compound 48/80 in 
caerulein-induced acute pancreatitis and CLP-induced sepsis were investigated and 
the impact of mast cell depletion on chemokines in different tissues was determined.  
 
  85
4.2  Results 
4.2.1 Mast cell depletion by compound 48/80 
Mast cells were depleted by compound 48/80 as described in methodology. As shown 
in Figure 22, the administration with compound 48/80 for three days depleted more 
than 80% mast cells in the mouse peritoneal cavity, which is consistent with previous 








4.2.2 Effect of mast cell depletion in caerulein-
induced acute pancreatitis 
Effect of mast cell depletion on local pancreatic injury was first investigated. 
Hyperstimulation of the pancreas by intraperitoneal administration of caerulein at a 
dose of 50 μg/kg hourly for 10 hours resulted in acute pancreatitis in mice. This was 
confirmed by an increase in plasma amylase (Figure 23 a), an increase in pancreatic 
water content as a measure of pancreatic edema (Figure 23 b), and an increase in 
pancreatic MPO activity (Figure 23 c) in mice treated with placebo and caerulein 
compared with control mice. Mast cell depletion by compound48/80 had no 
significant effect on plasma amylase levels and pancreatic MPO activity compared 
with those in animals treated with placebo (Figure 23 a and c). However, pancreatic 
water content in the pancreas was reduced in mast cell depleted mice (Figure 23 b), 
indicating that pancreatic edema was attenuated after mast cell depletion. Histological 
examination of pancreatic sections confirmed a lack of significant protective effect of 
mast cell depletion on local acute pancreatitis (Figure 24). Taken together, the results 
described above indicate that mast cell depletion has little protective effect against 




















Figure  24  Morphological  changes  in  pancreas  with  or  without  treatment  with 
compound 48/80 
(a)  Control,  no  pancreatitis;  (b)  Caerulein‐induced  acute  pancreatitis  in  mice 





It is well-established that in caerulein-induced acute pancreatitis model, local 
pancreatic injury was followed by a secondary respiratory distress syndrome in lung. 
Lungs from mice treated with caerulein had increased levels of MPO activity in 
comparison to control animals, suggesting neutrophil infiltration as a result of acute 
pancreatitis (Figure 25). Mast cell depletion significantly reduced lung MPO levels in 
caerulein-treated animals. Histology examination also showed the morphological 
changes in lung following induction of acute pancreatitis and the protective effect of 
mast cell depletion was observed as shown in Figure 26. Taken together, these data 
indicate that mast cell depletion has significant protective effect against acute 











Figure  26 Morphological  changes  in with  or without  treatment with  compound 
48/80 
(a)  Control,  no  pancreatitis;  (b)  Caerulein‐induced  acute  pancreatitis  in  mice 





To assess the role of mast cells in producing various chemokines in acute pancreatitis, 
MCP-1, MIP-1, RANTES and MIP-2 content in lung and pancreas were determined 
by ELISA. Mast cell depletion resulted in a down-regulation of several chemokines 
including MCP-1, MIP-1, RANTES and MIP-2 in lung (Figure 27) or in pancreas 
(Figure 28). These findings suggest that mast cell play a key role in modulating 

















IL-1 is an important pro-inflammatory mediator that can be produced by mast cells. 
In an attempt to determine the impact of mast cell depletion on IL-1 production, IL-
1 content in lung and pancreas were measured by ELISA. The results show that mast 









4.2.3 Effect of mast cell depletion in CLP-
induced sepsis  
The levels of MPO activity was increased in lung in CLP group in comparison to 
sham animals, suggesting neutrophil infiltration as a result of sepsis as shown in 
Figure 30. Mast cell depletion significantly reduced lung MPO levels. Histology 
examination also showed the morphological changes in lung following induction of 
sepsis and the protective effect of mast cell depletion was observed as shown in 
Figure 31. These data indicate that mast cell depletion has significant protective effect 

































Figure  31 Morphological  changes  in with  or without  treatment with  compound 
48/80 
(a)  Sham,  no  sepsis;  (b)  CLP‐induced  sepsis  in  mice  administered  placebo;  (c)  CLP‐




Liver failure is a common sequel of severe sepsis. The levels of MPO activity were 
increased in liver in CLP group in comparison to sham animals, suggesting neutrophil 
infiltration as a result of sepsis as shown in Figure 32.  Mast cell depletion had no 
significant effect on MPO levels in liver, indicating that mast cells do not play a 










































To assess the role of mast cells in producing various chemokines and pro-
inflammatory cytokine IL-1 in sepsis, MCP-1, MIP-1, and MIP-2 contents in lung 
and liver were determined by ELISA. Mast cell depletion resulted in a down-
regulation of several chemokines including CC chemokines MCP-1, MIP-1, and 
pro-inflammatory cytokine IL-1 (Figure 33 a-c), but had no effect on CXC 
chemokine MIP-2 (Figure 33 d) in mouse lung. In contrast, Mast cell depletion has 
little effect on these chemokines and IL-1 in liver (Figure 33 e-h). Taken together, 
these findings suggest that mast cells may play a key role in modulating chemokine 




Figure 33 Effect of mast cell depletion on chemokine and cytokine  levels  in  lung 
and liver 
Values are mean±SE for eight to ten animals in each group. PBS+CLP, placebo followed 
by  CLP;  Com+CLP,  mast  depletion  by  compound  48/80  followed  by  CLP.  “*”,  P<0.05 
versus placebo treated animals. 
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4.3  Discussion 
Our findings have shown that depletion of mast cells protects mice against acute 
pancreatitis associated lung injury, which is consistent with earlier studies using mast 
cell deficient mice (Bhatia, 1999). It has also been shown that pretreatment with the 
mast cell stabilizer cromolyn prevents pancreatitis-induced lung endothelial barrier 
dysfunction when acute pancreatitis was induced by the intraductal infusion of 5% 
sodium taurodeoxycholate in the rats (Zhao et al., 2005). In the same model, mast cell 
stabilizer (sodium cromoglycate) or antihistamines (pyrilamine, cyproheptadine, 
meclizine and amitriptyline) significantly reduce plasma exudation and MPO activity 
in lung (Dib et al., 2002). All these evidences suggest that mast cell activation may 
contribute to the sequential development of lung injury during acute pancreatitis.  
 
In this study, depletion of mast cell results in a significant decrease of water content in 
pancreas but has little effect on pancreatic MPO activity and plasma amylase. 
Histology examination also confirms no significant protective effect of mast cell 
depletion on local pancreatic injury.  Previous studies on the role of mast cells in local 
pancreas injury are conflicting. In the rat model of caerulein-induced acute 
pancreatitis, mast cell stabilizer ketotifen significantly reduced caerulein induced 
edema, neutrophil infiltration and attenuated the increase in amylase and MPO 
activity (Yonetci et al., 2001). However, in a rat model of acute pancreatitis that was 
induced by intraductal infusion of 5 per cent sodium taurodeoxycholate, mast cell 
stabilizer sodium cromoglycate has reduced MPO activity and MCP-1 levels in the 
colon and lung but have no effect in the pancreas (Dib et al., 2002). Moreover, in the 
same model, mast cell stimulation 30 min prior to induction of AP significantly 
reduces AP-induced tissue endothelial barrier dysfunction in the pancreas (Dib et al., 
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2002). In contrast, mast cell stimulation immediately after induction of AP results in a 
significant increase of tissue endothelial barrier dysfunction in pancreas (Dib et al., 
2002). All these findings indicate that mast cell might be involved in the development 
of local pancreatic inflammation. However, mechanisms seem to be complex and are 
still to be elucidated.  
 
Our study has shown that mast cell depletion has a protective effect against sepsis-
associated lung injury by attenuating chemokine production and neutrophil 
infiltration. In contrast, earlier studies show that mast cell deficient mice present 
reduced neutrophil migration into the peritoneal cavity with consequent limited 
clearance of bacteria, decreased TNF- and high mortality compared to wild type in 
CLP-induced sepsis (Echtenacher et al., 1996). One possible explanation is that 
different CLP models were used. In Echtenacher et al.’s study, the mortality observed 
in wild type mice was only around 30% after 10 days because they may probably use 
smaller size of needles to puncture or punctured only once. The CLP model used in 
our lab lead to more severe sepsis with a mortality rate of 100% in around 3 days 
(Puneet et al., 2006). It seems that mast cell may regulate host response that either 
confers benefit or harm, depending on the specific circumstances and severity of 
systemic inflammatory response during sepsis. In mild sepsis, mast cells may play a 
beneficial role by producing an appropriate amount of inflammatory mediators to 
promote host defense against infection. In contrast, in severe form of sepsis, mast 
cells may play a deleterious role by exaggerating the host pro-inflammatory response 
that leads to tissue damages. 
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The present study has shown that in acute pancreatitis and sepsis, mast cell depletion 
has different effect on chemokine production and inflammatory response in different 
organs such as lung, liver and pancreas. It has been known that mast cells are 
heterogeneous, and specific mast cell sub-populations from distinct tissues and 
species have varied mediator profiles and different functional properties. Future work 
has to be done to characterize the subpopulation of mast cells in different tissues in 
different species and to illustrate their specific response to acute inflammation in 
different models.  
 
Our study has shown that the depletion of mast cells results in a decrease of several 
chemokines and pro-inflammatory cytokine IL-1, indicating that mast cell may be an 
important source of chemokines in acute pancreatitis and sepsis. Besides their ability 
to directly produce various chemokines, mast cells may enhance leukocyte infiltration 
through indirect effect on endothelial cells. For example, mast cells releases tryptase 
that induces both mRNA expression and secretion of IL-8 from human vein 
endothelial cells (Compton et al., 1998). Activated mast cells can also produce TNF- 
that plays an important role in up-regulating the expression of ICAM-1 on endothelial 
cells. Other mast cell-derived mediators such as IL-4 and IL-13 may further up-
regulate the expression of VCAM-1 on endothelial cells in a synergistic manner with 
TNF- (Bochner et al., 1995). The up-regulation of adhesion molecules on 
endothelial cells may enhance neutrophil adhesion and infiltration in acute 
pancreatitis and sepsis.  Moreover, recent study has shown that mast cells may also 
alter phenotypes of adhesion molecules on leukocyte membrane (Zhao et al., 2005). 
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In summary, in acute pancreatitis and sepsis, mast cell depletion leads to down-
regulation of various chemokines in lung. Mast cells depletion may have protective 
effect against acute pancreatitis-associated lung injury by attenuating neutrophil 
infiltration but have little effect on local pancreatic injury. Mast cell depletion in 
severe sepsis may have a similar protective effect against sepsis-associated lung 




V. Fractalkine, a CX3C chemokine, is 
capable of modulating inflammatory 
response in caerulein-induced acute 
pancreatitis and CLP-induced sepsis 
5.1 Introduction 
Fractalkine (FTK), the sole member of CX3C chemokine family, has a unique 
structure: CX3C chemokine domain is attached on top of an extended mucin-like 
stalk.  Membrane-bound FTK can be cleaved from the cell membrane by proteolysis 
to yield soluble FTK(sFTK) (Garton et al., 2001; Ludwig et al., 2002). FTK has dual 
function in vivo: it behaves as a classic chemokine in its soluble form, whereas it acts 
as an adhesion molecule in its membrane-bound form (Bazan et al., 1997). FTK has 
been shown to be expressed on endothelial cells, dendritic cells and neurons and is 
distributed in a variety of organs (Bazan et al., 1997; Harrison et al., 1998; 
Papadopoulos et al., 1999). 
 
Only one chemokine receptor for FTK has been identified until now and is termed as 
CX3CR1. CX3CR1 is mainly expressed on monocytes, NK cells and T cells (Imai et 
al., 1997; Jung et al., 2000). In the brain, this receptor is mainly expressed by 
microglial cells and mediates protective anti-inflammatory effect against 
neurotoxicity (Cardona et al., 2006). Previous studies have shown that murine sFTK 
can induce neutrophil and lymphocyte chemotaxis in vitro and induce neutrophil, 
monocyte, lymphocyte infiltration to the peritoneum after i.p. injection (Pan et al., 
1997). In vitro experiments have shown that membrane-bound FTK mediates 
adhesion in a manner independent of signaling transduction  and integrin activation, 
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representing a novel mechanism in leukocyte migration (Fong et al., 1998; Haskell et 
al., 1999). These findings suggest that FTK may be involved in the process of 
leukocyte migration during innate inflammatory response. 
 
It has been shown that FTK is involved in the pathogenesis of several diseases 
including atherosclerosis, cancer, AIDS and etc (Becker, 2007; Braunersreuther et al., 
2007; Zhang et al., 2007) Little is known, however, about the role of FTK in 
pathogenesis of SIRS. The purpose of this study, therefore, is to investigate the 







5.2.1 FTK in caerule-induced acute pancreatitis  
Levels of endogenous FTK in plasma in caerule-induced acute pancreatitis model 
were determined by ELISA. As shown in Figure 34, 10 hours after the induction of 
acute pancreatitis, plasma FTK levels were no elevated compared with control group. 
I.p. injection of recombinant sFTK led to a significant elevation of plasma FTK levels 
in acute pancreatitis model. 
 


























The impact of exogenous sFTK during experimental acute pancreatitis was 
investigated. Hyperstimulation of the pancreas by i.p. administration of caerulein at a 
dose of 50 μg/kg hourly for 10 hours resulted in acute pancreatitis in mice. This was 
confirmed by an increase in plasma amylase (Figure 35 a), an increase in pancreatic 
MPO as a measure of neutrophil infiltration (Figure 35 b), and  an increase in 
pancreatic water content as a measure of pancreatic edema (Figure 35 c) in mice 
treated with caerulein compared with control mice. In animals administered sFTK 30 
minutes before the first injection of caerulein, plasma amylase levels, MPO activity 
and pancreatic water content were unchanged compared with those in animals treated 
with caerulein as shown in Figure 35. Taken together, these observations indicate that 
exogenous sFTK has little effect on local pancreatic injury.  
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It is well-established that in caerulein-induced acute pancreatitis model, local 
pancreatic injury was followed by a secondary respiratory distress syndrome in lung. 
Lungs from mice treated with caerulein had increased levels of MPO activity in 
comparison to control animals, suggesting neutrophil infiltration as a result of the 
pancreatitis (Figure 36). Administration of sFTK 30 minutes before the first caerulein 
injection significantly increased lung MPO levels in caerulein-treated animals as 
shown in Figure 36, indicating sFTK may induce neutrophil infiltration in lung. 
Histology examination showed the morphological changes in lung following 
induction of acute pancreatitis and the treatment with sFTK shows no protective effect 
on lung injury as shown in Figure 37. Taken together, these observations indicate that 
exogenous sFTK has little protective effect against acute pancreatitis-associated lung 
injury. 












































To assess the impact of sFTK administration on the levels of chemokines and 
proinflammatory cytokines in acute pancreatitis, MIP-2, MCP-1, IL-1 and TNF- 
content in lung and pancreas were determined by ELISA. Administration of sFTK 30 
minutes before the first injection of caerulein resulted in up-regulation of chemokines 
MCP-1, MIP-2, and cytokines IL-1, TNF- in lung (Figure 38). In contrast, 
administration of sFTK has little effect on the levels of these chemokines and 
cytokines in pancreas as shown in Figure 39. These observations have demonstrated 
that sFTK has distinct effect on the production of chemokine and cytokine in different 
tissues. 
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5.2.2 FTK in CLP-induced sepsis 
Levels of endogenous FTK in plasma in CLP-induced sepsis model were determined 
by ELISA. As shown in Figure 40, 24 hours after CLP operation, plasma FTK levels 
were elevated compared with sham group. I.p. injection of recombinant sFTK led to a 


















Mice  were  randomly  divided  into  three  groups:  SH  (mice  were  subjected  to  sham 
procedure),  CLP  (mice  were  subjected  to  CLP  procedure)  and  FTKCLP  (mice  were 
administered soluble FTK and were subjected to CLP procedure 30 min later). 24 hours 
after CLP operation plasma FTK levels were measured by ELISA. Results shown are the 




The expression of FTK and its corresponding receptor CX3CR1 in lung during sepsis 
was determined by RT-PCR. FTK mRNA expression was up-regulated, while 
CX3CR1 mRNA expression was down-regulated in lung during sepsis as shown in 
Figure 41 A. Similarly, it has been reported that FTK expression in lung of rats was 
increased with lipopolysaccharide (LPS)-induced sepsis (Beck et al., 2003). ELISA 
results also show that 24 hours after CLP operation, FTK levels increased in lung 
tissues Figure 41 B, which is consistent with RT-PCR results.  
 
The effect of sFTK on sepsis-associated lung injury was investigated. In lung, 
injection of soluble FTK attenuated MPO activity compared with CLP group, 
indicating that sFTK may reduce neutrophil infiltration into the lungs in CLP-induced 
sepsis. To further investigate the effect of sFTK on sepsis-associated lung injury, the 
morphological changes in lung were examined in each group as shown in Figure 42. 
The lungs sections from sham group showed no sign of inflammation. The lungs from 
CLP group exhibited characteristic signs of lung injury including alveolar thickening 
and severe leukocyte infiltration. Administration of sFTK attenuated these signs of 
inflammation.  Taken together, these observations indicate that exogenous sFTK has a 








the  mean±SE  for  six  to  eight  mice  in  each  group.  SH  (mice  were  subjected  to  sham 
procedure),  CLP  (mice  were  subjected  to  CLP  procedure)  and  FTKCLP  (mice  were 













To assess the impact of sFTK administration on chemokines in lung, the levels of 
chemokines including CXC chemokine MIP-2 and CC chemokines MCP-1, MIP-1 
were measured by ELISA as shown in Figure 43. sFTK has little effect on CC 
chemokines: MCP-1 and MIP-1, however, it significantly down-regulate CXC 
chemokine MIP-2 levels in lung. Since MIP-2 is a potent inducer of neutrophil 
infiltration, soluble FTK-induced MIP-2 down-regulation might contribute to the 
attenuation of MPO activity. The results have also shown that sFTK down-regulated 
two pro-inflammatory cytokines IL-6 and IL-1 levels but had no effect on an anti-
inflammatory cytokine IL-10 as shown in Figure 43. These findings suggest that 
soluble FTK may be capable of regulating the production of some chemokines and 




24 hours  after  CLP operation  lung MIP‐2, MCP‐1, MIP‐1,  IL‐6,  IL‐1  and  IL‐10  levels 
were measured. Results  shown are  the mean±SE  for  six  to eight mice animals  in each 
group. SH (mice were subjected to sham procedure), CLP (mice were subjected to CLP 
procedure)  and  FTKCLP  (mice were  administered  soluble  FTK  and were  subjected  to 





It is well-established that leukocyte infiltration is a coordinated multi-step process, 
including leukocyte rolling, adhesion and extravasation. It is still unknown at which 
step exogenous sFTK attenuates leukocyte infiltration during sepsis. To address this 
question, intravital microscope was employed to observe the effect of sFTK on 
leukocyte infiltration in vivo as described in Materials and Methods. As shown in 
Figure 44, in CLP group the number of the rolling cells and adherent cells is greatly 
increased compared with sham group. Meanwhile, the rolling velocity was 
significantly decreased in CLP group. sFTK significantly decreased the number of 
adherent cells compared with CLP groups; however, sFTK has little effect on the 
number of rolling cells and the rolling velocity. These findings suggest that sFTK may 
have an inhibitory effect on leukocyte adhesion in vivo probably by preventing the 








microscopy  assay.  SH  (mice  were  subjected  to  sham  procedure),  CLP  (mice  were 
subjected  to  CLP  procedure)  and  FTKCLP  (mice  were  administered  sFTK  and  were 
subjected  to  CLP  procedure  30  min  later).  The  parameters  were  evaluated  16  hours 
after the CLP procedure. Results shown are the mean±SE (n=4 animals in each group). 




The levels of endogenous FTK in plasma were determined in animal models of acute 
pancreatitis and sepsis. 24 hours after CLP operation, a 3-fold increase of FTK levels 
in plasma was observed. It is consistent with a recent clinical study showing that FTK 
serum concentrations were elevated in sepsis patients (Pachot et al., 2008). LPS and 
pro-inflammatory cytokines TNF- and IL-1 may increase the expression of FTK on 
endothelial cells during inflammation by activating NF-κB (Garcia et al., 2000). 
Membrane-bound FTK can be cleaved from the cell membrane by proteolysis to yield 
s-FTK that may be released into the plasma (Garton et al., 2001; Ludwig et al., 2002). 
In contrast, after 10 hours of caerulein injection, plasma FTK levels did not increased 
compared with control animals. It is still not clear whether it is because the 
stimulators of FTK expression are less potent in AP or because the cleavage of FTK is 
less efficient in acute pancreatitis.  
 
Previous studies have shown the expression of FTK at mRNA levels in human and 
murine lungs (Bazan et al., 1997; Pan et al., 1997). FTK expression has been 
observed on endothelial cells, on bronchial epithelial cells and airway smooth muscle 
cells in lung (Balabanian et al., 2002; Sukkar et al., 2004). The present study has 
shown that in sepsis model, the expression of FTK was up-regulated in lung. It is 
consistent with previous report that FTK expression is increased in lung, kidney and 
intestine of rats in LPS-induced sepsis (Beck et al., 2003; Sung et al., 2005). In 
contrast, CX3CR1, the receptor for FTK, is constitutively expressed at mRNA levels 
in lung and is down-regulated 24h after CLP operation. Clinical study has shown that 
CX3CR1 expression (both mRNA and protein) was severely down-regulated in 
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monocytes in sepsis patients, which might account for the decrease of 
CX3CR1expression in lung (Pachot et al., 2008). 
 
To study the role of sFTK, recombinant sFTK was injected into the mice which led to 
an increased FTK levels in plasma in acute pancreatitis and sepsis. In acute 
pancreatitis, administration of sFTK leads to a further increase of neutrophil 
infiltration as shown by MPO activity. Soluble chemokine domain of mouse FTK was 
reported to induce neutrophils and T-lymphocytes and monocytes migration in vivo 
(Pan et al., 1997), although FTK is a less potent neutrophil chemoattract than IL-8 
and MCP-1 (Beck et al., 2003). In CLP-induced sepsis, after the administration of 
sFTK, MPO activity in lung was attenuated, indicating that sFTK reduces neutrophil 
infiltration in lung which may contribute to the beneficial effect of sFTK on lung 
injury. It has been reported that sFTK can prevent MCP-1-induced monocyte 
migration in vitro (Vitale et al., 2004). It is still unclear whether FTK affects 
neutrophil infiltration directly or indirectly by modulating the response of pro-
inflammatory cytokines and chemokines. 
 
Interestingly, sFTK increases neutrophil infiltration and chemokine and cytokine 
production in lung in acute pancreatitis, while sFTK attenuates neutrophil infiltration 
and chemokine and cytokine production in lung in sepsis. The exact mechanisms 
remain to be elucidated. FTK seems to have both pro-inflammatory effect and anti-
inflammatory effect. On the one hand, previous study shows that FTK preferentially 
mediates arrest and migration of CD16+ monocytes, suggesting that recruitment of 
this pro-inflammatory monocyte subset to vessel walls via the CX3CR1-FTK pathway 
may contribute to vascular and tissue injury during pathological conditions (Ancuta et 
  122
al., 2003). FTK may also attract T-lymphocytes, dendritic cells and neutrophils into 
the inflamed tissues, exacerbating the tissue injury (Niess et al., 2005; Pan et al., 
1997). On the other hand, FTK directly promotes monocyte anti-inflammatory and 
anti-procoagulant responses (Ollivier et al., 2003). Moreover, dose-dependent dual 
effects of FTK have been described in macrophages. A recent in vitro study shows 
that macrophages pretreated with 0.03 nM FTK but not with 3 nM FTK secreted 50% 
less TNF-alpha than did cells treated with LPS alone, indicating a dose-dependent 
differential regulation of cytokine secretion by FTK (Mizutani et al., 2007). It is 
notable that after the administration of sFTK, the FTK levels in plasma increased to 
about 4000 pg/ml in caerulein-induced acute pancreatitis and to about 8000 pg/ml in 
CLP-induced sepsis. In vivo, the effect of FTK may be more complicated because 
FTK may interact with other inflammatory mediators. For example, it has been 
reported that sFTK can prevent MCP-1-induced monocyte migration (Vitale et al., 
2004), while MCP-1 stimulates surface expression of CX3CR1 and enhances the 
adhesion of monocytes to FTK (Green et al., 2006). Future work has to be done 
before we can fully understand the complex effect of FTK in SIRS. 
 
It is well recognized that leukocyte migration is a multiple step process including cell 
rolling, adhesion and extravasation. Intravital microscopy has shown for the first time 
that the administration of sFTK significantly reduced the number of adherent 
leukocytes but has little effect on leukocyte rolling, which indicates that sFTK may 
reduce leukocyte migration into the lungs by interfering leukocyte adhesion during 
sepsis. It has been known that in vitro sFTK completely suppresses cell adhesion to 
immobilized FTK (Imai et al., 1997). Our findings have provided novel insights on 
FTK’s adhesion properties in vivo during sepsis. 
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In summary, the present study has shown that exogenous soluble FTK increase 
neutrophil infiltration and chemokine and cytokine production in lung in acute 
pancreatitis. In contrast, sFTK attenuates leukocyte adhesion and migration in lung in 
CLP-induced sepsis. Treatment with soluble FTK has a protective effect against 
sepsis-associated lung injury by reducing neutrophil infiltration, leukocyte adhesion 
and chemokine and cytokine production in lung. One recent study shows that 
exogenous sFTK have a beneficial effect in sepsis by enhancing apoptotic cell 
clearance by macrophages (Miksa et al., 2007). Further studies are needed to reveal 
other possible functions of FTK during acute pancreatitis and sepsis. 
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VI. General discussion 
When chemokines and their receptors were first characterized, the strategy to block 
chemokines seems not very attractive due to the suspicion that blockage of single 
ligand-receptor interaction may have no significant effect in this redundant system. 
Obviously, many chemokines binds to more than one receptor and many receptors 
have several potent ligands. However, early studies on specific chemokine receptor 
knockout mice have shown that many chemokine receptors have indispensable 
functions in various disease conditions, indicating that the approach to block one 
chemokine receptor may have significant beneficial impact on the final outcome of 
various diseases.  In recent years, many small molecule antagonists against specific 
human chemokine receptors have been developed due to the efforts of 
pharmacological industry but most of them do not have cross-species antagonizing 
activity in rodents, making it difficult to validate their therapeutic effect in rodent 
animal models. Fortunately, BX471, the small molecule CCR1 antagonist used in this 
study, has cross-species activity in mouse. Our findings animal models of acute 
pancreatitis and sepsis demonstrate that CCR1 is a non-redundant effective drug 
target in SIRS, which further confirms that the strategy of blockage of one member of 
chemokine receptor family is feasible to reverse some aspects of systemic 
inflammation response.  
 
Despite the fact that most chemokines are evolutionarily closely related, many 
members may have distinct functions in the same disease. For example, in present 
study, blockage of CCR1 attenuates acute pancreatitis-associated lung injury but have 
little effect against local pancreatic injury. In contrast, treatment with bindarit, a 
blocker of MCP-1 (CCR2 main ligand) synthesis, protects mice against local acute 
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pancreatic injury (Bhatia et al., 2005). Thus, interfering different members of CC 
chemokine subfamily may have distinct influences on the outcome of acute 
pancreatitis. However, the underlying mechanisms that lead to these distinct 
influences are not clear yet.  
 
Blockage of CC chemokines or their receptor leads to the attenuation of neutrophil 
infiltration in both sepsis and acute pancreatitis, which further challenges the old 
notion that CC chemokines mediate monocyte migration while CXC chemokines 
mediate neutrophil migration.  The function of CC chemokines in acute inflammation 
should not be ignored. CXC chemokines and their receptors are also attractive drug 
targets in animal models of acute pancreatitis and sepsis due to their capability of 
mediating neutrophil infiltration.   
 
In acute pancreatitis and sepsis, mast cell depletion has different effect on 
inflammatory response in different organs including lung, liver and pancreas. Our 
study and other researchers’ reports have shown that depletion of mast cells or 
treatment with mast cell stabilizer has protective effect against acute pancreatitis 
associated lung injury (Dib et al., 2002; Zhao et al., 2005). However, whether 
depletion of mast cell has a beneficial effect in sepsis seems to depend on the severity 
of disease and the magnitude of inflammatory response (Echtenacher et al., 1996). As 
sepsis is an infectious cause of SIRS while acute pancreatitis is a non-infectious cause 
of SIRS, more caution should be taken to maintain the host defense in sepsis. Any 
interference that might compromise the elimination of initiating pathogens might 
increase the risk of mortality in sepsis.  
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CX3C chemokine FTK acts as an adhesion molecule on endothelial cells, while acts 
as classic chemokines only after cleavage. Plasma levels of FTK are elevated in sepsis 
but not in acute pancreatitis. The present study has shown that administration of 
exogenous soluble form of fractalkine protects against sepsis associated lung injury 
by attenuating neutrophil infiltration, leukocyte adhesion and chemokine and cytokine 
production. New drugs mimicking the function of soluble fractalkine might have 
therapeutic potential for sepsis.  
 
6.1 Limitations 
In the present study, all the findings are mainly based on two animal models: 
caerulein-induced acute pancreatitis and CLP-induced sepsis. Although some new 
promising therapeutic approaches are indentified in animal models in this study, these 
approaches must be tested in clinical trials on patients before we are fully convinced 
about their effect in patients. Numerous trials were conducted of agents that block the 
inflammatory cascade-corticosteroids, anti-endotoxin antibodies, tumor necrosis 
factor antagonists, IL-1 receptor antagonists, and other agents in sepsis patients. 
Unfortunately, most of these attempts have been largely unsuccessful despite 
promising beneficial effect in animal models. The caerulein model of pancreatitis 
appears to reflect many of the changes found in human disease. However, the most 
important limitation of this model is that only a mild self-limited disorder is 
generated, which is of limited use for studying the more destructive aspects of the 
disease which confer clinical morbidity and death.  
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It is beyond the scope of our study to illustrate all the intriguing functions of 
chemokines in acute pancreatitis and sepsis. Compared with chemokine receptors that 
are expressed on leukocytes that have been studied extensively, the functions of 
chemokine receptors that are expressed on non-hematopoietic cells in different tissues 
in SIRS have not been covered in the present study. One recent study shows that 
activation of CXCR2 on endothelial cells result in rapid actin polymerization and 
formation of stress fibers, ultimately leading to a retraction of these cells, indicating 
potential of endothelial CXCR2 to directly mediate vascular permeability (Reutershan 
et al., 2006). Recently, chemokine receptor activity has also been detected on DRG 
neurons. That a proinflammatory chemokine, by interacting with its receptor on 
small-diameter neurons, sensitizes TRPV1 reveals a previously undescribed 
mechanism of receptor cross-sensitization that may contribute to hyperalgesia during 
inflammation (Zhang et al., 2005). Thus, the role of chemokine receptors on 
endothelial cells and neurons in SIRS is worth investigating in future studies.  
 
6.2 Future research 
The hypothesis that co-administration of CC and CXC chemokine receptor 
antagonists can have a more potent inhibitory effect on neutrophil infiltration and 
provide more significant protection against acute inflammation should be tested in the 
future study. Besides small molecule antagonists for one specific chemokine receptor, 
several broad-spectrum chemokine inhibitors that broadly inhibit the function of a 
wide range of chemokines have been developed and tested in several animal models 
of inflammation including LPS-induced sepsis (Grainger and Reckless, 2003). 
Despite their inhibitory effect on leukocyte infiltration in vivo, the molecular 
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mechanism by which they specifically block chemokine-induced migration remains 
largely elusive. Caution must be taken because of possible side-effect of these 
inhibitors in SIRS.  
 
Some large DNA viruses may have millions of years of experience in manipulating 
chemokine system. Studies on virally encoded chemokine receptor antagonists have 
illustrated new strategies to develop new types of chemokine-modulatory drugs. 
Human herpesvirus 8 has developed a surprisingly broad-spectred chemokine receptor 
antagonist called vMIP-II (virally encoded macrophage inflammatory protein II), 
which fully antagonizes the signaling of six out of the 18 human chemokine receptors 
and therefore affects all four types of chemokine receptors (CC, CXC, CX3C and C 
receptors) (Lindow et al., 2003). Moreover, many poxviruses encode two different 
chemokine binding (neutralizing) proteins (CBPs): CBP-Is, which bind and block the 
conserved, glycosaminoglycan (GAG) binding epitope on the chemokines; and CBP-
IIs, which bind and cover the receptor binding epitopes of most of the 28 members of 
CC-chemokine family chemokines (Lindow et al., 2003). New drug targeting GAG 
binding site of chemokines might be very potent in inhibiting leukocyte infiltration 
because these drugs may be able to eradicate the local concentration gradient of all 
chemokines around inflammatory sites and thereby destroying the directionality of the 
leukocyte infiltration. The influences of this approach in acute pancreatitis and sepsis 
have to be investigated in future studies.   
 
Other than signaling chemokine receptors mediating leukocyte recruitment during 
inflammatory reactions, the chemokine system also includes ‘silent’ receptors with 
distinct specificity and tissue distribution. The best-characterized molecule of this 
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subgroup is the CC chemokine receptor D6, which binds most inflammatory CC 
chemokines and targets them to degradation via constitutive ligand-independent 
internalization (Borroni et al., 2006; Jamieson et al., 2005; Martinez de la Torre et al., 
2005). The potential protective function of this special chemokine receptor D6 in 
acute pancreatitis and sepsis could be investigated in future work. 
 
In conclusion, our study has shown that blockage of CCR1 by a small molecule CCR1 
antagonist has protective effect against acute lung injury in animal models of acute 
pancreatitis and sepsis. Depletion of mast cells by compound 48/80 also attenuated 
acute pancreatitis-associated lung injury and sepsis-associated lung injury by 
attenuating the levels of chemokines. Treatment with an exogenous CX3C chemokine 
FTK has shown pro-inflammatory effect in acute pancreatitis-associated lung injury 
and anti-inflammatory effect against sepsis-associated lung injury. These promising 
findings validate that manipulating chemokine system may have protective effect in 
systemic inflammatory response syndrome in animal models of acute pancreatitis and 
sepsis. Our results also show that in acute pancreatitis and sepsis, chemokines may 
interact with adhesion molecules, cytokines and control neutrophil infiltration. The 
therapeutic potential of small molecule CCR1 antagonist in acute pancreatitis and 
sepsis is still to be validated in human clinical trials. New drug targets in the 
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